

## **CURRICULUM VITAE:**

Jeffrey M. Switchenko, Ph.D.

Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University  
Biostatistics Shared Resource, Winship Cancer Institute, Emory University  
1518 Clifton Road NE, Atlanta GA 30322  
(404) 778-4157, jswitch@emory.edu

---

### **EDUCATION:**

Ph.D. in Biostatistics, Emory University, December 2011

Advisor: Dr. Lance Waller

Dissertation Title: “Estimation of Epidemic Model Parameters: A Spatial Analysis using Bayesian Techniques”

M.S. in Biostatistics, Emory University, December 2010

B.A. in Mathematics, Bowdoin College, May 2006

---

### **WORK EXPERIENCE:**

Associate Professor (Research-track), Department of Biostatistics and Bioinformatics, Emory University, April 2022 – Present.

Assistant Professor (Research-track), Department of Biostatistics and Bioinformatics, Emory University, February 2012 – April 2022.

Scientific Director, Biostatistics Shared Resource, Winship Cancer Institute, Emory University, May 2022 – Present.

Interim Director, Biostatistics Shared Resource, Winship Cancer Institute, Emory University, October 2020 – May 2022.

Assistant Director, Biostatistics Shared Resource, Winship Cancer Institute, Emory University, March 2020 – October 2020.

Statistician, Biostatistics Consulting Center, Emory University, May 2007 – December 2011.

Statistician, Centers for Disease Control and Prevention (ORISE Fellow), September 2011 – January 2012.

Research Assistant, Department of Biostatistics and Bioinformatics, Emory University, May 2007 – August 2007.

Intern, E Ink Corporation, Summers 2003 – 2006.

---

### **TEACHING:**

#### *Courses taught:*

Bios 506, Emory University, Fall 2019, 2020, 2021, 2022

Introduction to Clinical Trial Design, MSCR program, Emory University, Spring 2018, 2019, 2020, 2021, 2022, 2023

Bios 500 Lab, Emory University, Fall 2008, 2009, 2010, 2011

Bios 501 Lab, Emory University, Spring 2009, 2011, 2016

#### *Student mentoring:*

Thesis/Capstone Advisor

Ram Siwakoti, MSPH Biostatistics – 2019

Luer Zhong, MSPH Biostatistics – 2019

Chenhao Lu, MSPH Biostatistics – 2020

Nikhila Gandrakota, MPH Epidemiology – 2020 (co-advisor)

Xiaona Li, MPH Biostatistics – 2021

Hannah Kalvin, MSPH Biostatistics – 2021

Yuxi Liu, MPH Biostatistics – 2021

Yan Su, MPH Biostatistics – 2021

Nicolas Toumbacaris, MSPH Biostatistics – 2022

Elizabeth Fogleman, MPH Biostatistics – 2022

Melanie Quezada, Applied Epidemiology MPH – 2022

Samantha Gagnon, Applied Epidemiology EPMH – 2022

Shannon Ju, MPH Biostatistics – 2023

#### Thesis/Capstone committee

Brianna McDaniels, Genetic Counseling Training Program, SOM –2018

Lee Kugelman, Genetic Counseling Training Program, SOM – 2019

Robyn Fernando, MSPH Epidemiology – 2019

Elyse Zhang, PhD Health Policy and Management – 2022

#### Thesis Reader

Xingyu Gao, MPH Biostatistics – 2021

Troy Kleber, MSCR – 2022

Zirong Yu, MPH Biostatistics – 2023

#### Faculty Mentor – Department of Biostatistics and Bioinformatics

Raphael Murden, Research Assistant Professor

Tarrant McPherson, Research Assistant Professor

#### Faculty Mentor – Discovery Phase

Lindsay Clough – 2019

Timothy Niyugosaba – 2023

Charles Marvil – 2023

#### Faculty Mentor – Winship K12 Clinical Oncology Training Program

Michelle Schoettler – 2021

#### Advisory committee member – MSCR program

Andrew Ip – 2018

Troy Kleber – 2021

David Bray – 2022

Reema Martini – 2023

#### Faculty Oversight Committee – Pediatric Hematology Oncology Fellowship Program

Frank Chien – 2021-present

#### Directed studies

Benjamin Flink – 2015

#### Research assistants

Wendi Liang – 2016

#### Practicums

Erin Hulland – 2013

Yunyun Chen – 2015

Tianqi Chen – 2016

Silu Liu – 2016

En Cheng – 2016

Xingyu Gao – 2020

Yan Su – 2020

Zihe Song – 2020

Jiahui Jiang – 2020

Hannah Kalvin – 2020  
Nicolas Toumbacaris – 2021  
Yixuan Li – 2022  
Zirong Yu – 2022  
Chenxi Du – 2022  
Zhenyu Situ – 2022  
Brielle Berkowitz – 2022

Mentor – Coursework

BIOS 745R – Biostatistical Consulting

Gabrielle Breen – 2013  
Devin Liao – 2014  
Caprichia Jeffers – 2014  
Lael Rayfield – 2016  
Yikai Wang – 2016  
Teng Fei – 2017  
Zhenxing Guo – 2018  
Yiman Li – 2018  
Yuzi Zhang – 2019

Fundamentals in Clinical Research

Andres Chang – 2017  
Andrew Ip – 2017

EH 583 – Spatial Analysis of Disease Ecology

Stephanie Smith – 2018

AACR/ASCO Methods in Clinical Cancer Research Workshop

Michael Turgeon – 2020  
Michael Lowe – 2020

Mentor – Grant submissions

Kate Yeager – 2012, K01 award  
Gelareh Sadigh – 2016, RSNA research grant  
Waaqo Daddacha – 2018, K01 award  
Jean Koff – 2018, K08 award  
Zachary Buchwald – 2018, K08 award  
Neil Pfister – 2018, Conquer Cancer Foundation award  
Andres Chang – 2018, Conquer Cancer Foundation award  
Andrew Ip – 2018, Conquer Cancer Foundation award  
Vinita Singh – 2019, K23 award  
Manali Bhavé – 2019, Conquer Cancer Foundation award  
Lisa Sudmeier – 2019, ASCO Young Investigator Award  
Sanjay Chandrasekaran – 2019, ASCO Young Investigator Award  
Neil Pfister – 2019, K08 award  
Zachary Buchwald – 2020, K12 award  
Mehmet Akce – 2020, K08 award  
Jason Romancik – 2020, ASCO Young Investigator Award  
Zachary Buchwald – 2020, Conquer Cancer Foundation Award  
Troy Kleber – 2020, American Brain Tumor Association  
Ruth Sacks – 2021, K12 award  
Manali Bhavé – 2021, K12 award  
Mehmet Akce, 2021, K08 award  
Zachary Buchwald – 2021, ASTRO-MRA YIA in Radiation Oncology

Jeffrey Aldrich – 2021, ASCO Young Investigator Award  
Rami Atallah – 2021, ASCO Young Investigator Award  
Deepthi Kodali – 2021, ASCO Young Investigator Award  
Sandra Kang – 2021, ASCO Young Investigator Award  
David Qian – 2021, ASCO Young Investigator Award  
Jeff Aldrich – 2022, ASCO Young Investigator Award  
Sarah Wood – 2022, ASCO Young Investigator Award  
Elizabeth Sakach – 2022, ASCO Young Investigator Award  
Mihir Shah – 2022, K12 award  
Andres Chang, 2022, K08 award

Faculty advisor

Ram Siwakoti – 2017-19  
Chenhao Lu – 2018-20  
Qingyu Wang – 2018-20  
Yanlong Yu – 2018-20  
Xingyu Gao – 2019-21  
Zelin Wang – 2020-22  
Qingyi Wang – 2020-22  
Sam Yin – 2020-Present

Qualifying exam tutor

Kylie Ainslie – 2013

*Invited lecture talks:*

- “Study Design”, School of Medicine (SOM) Clinical Research Bootcamp 101, April 14<sup>th</sup>, 2023
- “Winship Cancer Institute: Biostatistics Shared Resource – An overview”, Bios 745R – Biostatistical Consulting, February 10<sup>th</sup>, 2023
- “Clinical Research Track Faculty Promotion”, Faculty panel, December 15<sup>th</sup>, 2022
- “Statistical Considerations: Design & Analysis”, Introduction to Clinical Research Course, October 24<sup>th</sup>, 2022
- “Statistical Designs for Phase 1 trials: beyond 3+3”, K12 Clinical Oncology Training Program Workshop, July 28<sup>th</sup>, 2022
- “Statistics in Cancer Research”, Winship Summer Scholars program, July 6<sup>th</sup>, 2022
- “Winship Cancer Institute: Biostatistics Shared Resource – An overview”, Bios 745R – Biostatistical Consulting, February 11<sup>th</sup>, 2022
- “Clinical Trials Webinar”, RSPH Admission Content-Specific Webinar, February 11<sup>th</sup>, 2022
- “Clinical Trials conversation”, Explore Emory, February 3<sup>rd</sup>, 2022
- “Operating your small business”, Faculty panel, Public Health Research: From Discovery to Practice PUBH 701, October 29<sup>th</sup>, 2021
- “Statistical Considerations: Design & Analysis”, Introduction to Clinical Research Course, August 9<sup>th</sup>, 2021

- “Statistical Designs for Phase 1 trials: beyond 3+3”, K12 Clinical Oncology Training Program Workshop, July 15<sup>th</sup>, 2021
- “Statistics in Cancer Research”, Winship Summer Scholars program, June 30<sup>th</sup>, 2021
- “Clinical Trials Webinar”, RSPH Admission Content-Specific Webinar, February 10<sup>th</sup>, 2021
- “Clinical Trials conversation”, Explore Emory, February 4<sup>th</sup>, 2021
- “Strategic Planning in BIOS”, Faculty panel, Public Health Research: From Discovery to Practice PUBH 701, September 23<sup>rd</sup>, 2020
- “Statistical Designs for Phase 1 trials: beyond 3+3”, K12 Clinical Oncology Training Program Workshop, July 24<sup>th</sup>, 2020
- “Statistics in Cancer Research”, Winship Summer Scholars program, June 17<sup>th</sup>, 2020
- “Career Discussion Panel,” BIOS Diversity, Equity, and Inclusion Committee Seminar, February 27<sup>th</sup>, 2020
- “Cancer Research Panel,” Rollins Association for Cancer Prevention and Control (RACPAC), February 26<sup>th</sup>, 2020
- “Choosing exciting research directions”, Faculty panel, Public Health Research: From Discovery to Practice PUBH 701, September 16<sup>th</sup>, 2019
- Summer Institute in Biostatistics (SIBS) panel, June 26<sup>th</sup>, 2019
- “Statistics in Cancer Research”, Winship Summer Scholars program, June 13<sup>th</sup>, 2019
- “Winship Cancer Institute: Biostatistics and Bioinformatics Shared Resource – An overview”, Bios 745R – Biostatistical Consulting, October 5<sup>th</sup>, 2018
- “Statistics in Cancer Research”, Winship Summer Scholars program, June 19<sup>th</sup>, 2018
- “Geospatial exposure to benzene and lymphoma risk in Georgia,” Lymphoma Research Conference, Winship Cancer Institute, Emory University, February 22<sup>nd</sup>, 2018
- “Winship Cancer Institute: Biostatistics and Bioinformatics Shared Resource – An overview”, Bios 745R – Biostatistical Consulting, October 13<sup>th</sup>, 2017
- “Statistics in Cancer Research”, Winship Summer Scholars program, June 8<sup>th</sup>, 2017
- “Phase 2 trials”, Oncology Reviews Journal Club, November 21<sup>st</sup>, 2016
- “Winship Cancer Institute: Biostatistics and Bioinformatics Shared Resource – An overview”, Bios 745R – Biostatistical Consulting, October 14<sup>th</sup>, 2016
- “Statistics in Cancer Research”, Winship Summer Scholars program, June 23<sup>rd</sup>, 2016
- “NCDB Workshop II – The Framework of Statistical Collaboration”, National Cancer Database Workshop II, November 11<sup>th</sup>, 2015
- “Winship Cancer Institute: Biostatistics and Bioinformatics Shared Resource – An overview”, Bios 745R – Biostatistical Consulting, October 9<sup>th</sup>, 2015

- “Data Management and Analytic Checklist”, National Cancer Database Workshop I, August 3<sup>rd</sup>, 2015
- “Screening studies”, Oncology Reviews Journal Club, May 14<sup>th</sup>, 2015
- “Winship Cancer Institute: Biostatistics and Bioinformatics Shared Resource – An overview”, Bios 745R – Biostatistical Consulting, October 3<sup>rd</sup>, 2014
- “Descriptive measures”, Oncology Reviews Journal Club, February 27<sup>th</sup>, 2014
- “Winship Cancer Institute: Biostatistics and Bioinformatics Shared Resource – An overview”, Bios 745R – Biostatistical Consulting, October 4<sup>th</sup>, 2013
- “Descriptive measures”, Oncology Reviews Journal Club, March 28<sup>th</sup>, 2013
- “Assessment of associations between proximity to chemical release sites and incidence of lymphomas in Georgia, 1999-2008”, Cancer Prevention and Control monthly meeting, October 18<sup>th</sup>, 2012

---

## RESEARCH:

### *Peer Reviewed Publications:*

1. Maithel SK, Keilson JM, Cao HS, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. NEO-GAP: A single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Accepted by Annals of Surgical Oncology on 5/15/23.
2. Zhuang TZ, McCook-Veal AA, Switchenko JM, Niyogusaba T, Tarabadkar E, Baird K, O’Leary C, Paulino D, Lechowicz MJ, Allen PB. Characterizing outcomes in visceral cutaneous T-cell lymphoma: A single center retrospective study. Clinical Lymphoma, Leukemia & Myeloma. 2023 May 5; S2152-2650(23)00141-6. doi: 10.1016/j.clml.2023.05.001. Online ahead of print. PubMed PMID: 37271662.
3. Ajay PS, Sok C, Goyal S, Switchenko JM, Lin Y, Maegawa F, Gillespie TW, Paulos CM, Lesinski GB, Kooby DA, Kennedy TJ, Shah MM. Impact of nodal status in determining multimodal treatment strategies in non-cardia gastric cancer. Journal of Surgical Oncology. 2023 Apr 28. doi: 10.1002/jso.27297. Online ahead of print. PubMed PMID: 37114465.
4. Ajay PS, NeMoyer R, Goyal S, Switchenko JM, Lin Y, Jabbour SK, Carpizo DR, Paulos CM, Kennedy TJ, Shah MM. Does non-metastatic gastric cancer of the cardia warrant a different treatment strategy? Journal of Surgical Oncology. 2023 Apr 10. doi: 10.1002/jso.27276. Online ahead of print. PubMed PMID: 37036147.
5. McClary TS, Blee SM, Avinger AM, Dai Q, Switchenko JM, Dixon MD, Pentz RD. Accounting for the high enrollment of African Americans on Winship Cancer Institute’s Myeloma Clinical Trials. Ethics, Medicine and Public Health. 2023 Apr; 27:100877. doi: 10.1016/j.jemep.2023.100877. Epub 2023 Mar 3. PubMed PMID: 37007841.
6. Huels A, Van Cor S, Christensen G, Li Z, Liu Y, Shi L, Pearce JL, Bayakly R, Lask TL, Ward K, Switchenko JM. Environmental, social and behavioral risk factors in association with spatial clustering of childhood cancer incidence. Spatial and Spatio-temporal Epidemiology. 2023 Jun; 45:100582. PubMed PMID: 37301597; PubMed Central PMCID: PMC10258443.
7. Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, Portell CA, Mejia AV, Goldsmith SR, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar OS, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Advances. 2023 Feb 21: bloodadvances.2022008916. doi: 10.1182/bloodadvances.2022008916. Online ahead of print. PubMed PMID: 36809796.

8. Janopaul-Naylor JR, Cao Y, McCall NS, Switchenko JM, Tian S, Chen H, Stokes WA, Kesarwala AH, McDonald MW, Shelton JW, Bradley JD, Higgins KA. Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era. *Frontiers in Oncology*. 2023 Jan 17; 12:1074675. PubMed PMID: 36733369; PubMed Central PMCID: PMC9888533.
9. Olimpiadi Y, Goldenberg AR, Postlewait L, Gillespie T, Arciero C, Styblo T, Cao Y, Switchenko JM, Rizzo M. Outcomes of the same-day discharge following mastectomy before, during and after COVID-19 pandemic. *Journal of Surgical Oncology*. 2023 Apr; 127(5): 761-767. PubMed PMID: 36621857.
10. Lin J, Pfister N, McDonald MW, Patel P, Tian S, Gunthel CJ, Cao Y, Switchenko JM, Alese O, Landry JC. Factors impacting clinical outcomes among HIV-infected anal cancer patients treated with modern definitive chemotherapy and radiation therapy. *Advances in Radiation Oncology*. 2022 Dec 26; 8(2):101155. PubMed PMID: 36845623; PubMed Central PMCID: PMC9943777.
11. Janopaul-Naylor JR, Rupji M, Tobillo R, Lorenz JW, Switchenko JM, Tian S, Kaka AS, Qian DC, Steuer CE, Remick JS, Rudra S, McDonald M, Stokes W, Patel MR, Bates JE. Ninety-day mortality following TORS or radiation at Commission on Cancer-accredited facilities. *Head & Neck*. 2023 Mar; 45(3):658-663. PubMed PMID: 36549012.
12. Azzem M, Nooka AK, Shanmugasundaram U, Cheedarla N, Potdar S, Manalo J, Moreno A, Switchenko JM, Cheedarla S, Doxie D, Radzievski R, Ellis M, Manning K, Wali B, Valanparambil R, Baymon E, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Roback JD, Sette A, Ahmed R, Suthar MS, Neish AS, Dhodapkar MV, Dhodapkar KM. Impaired variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: Correlation with breakthrough infections. *Blood Cancer Discovery*. 2023 Mar 1; 4(2): 106-117. PubMed PMID: 36511813; PubMed Central PMCID: PMC9975771.
13. Chang A, Aktar A, Lai L, Orellana-Noia VM, Linderman SL, McCook-Veal AA, Switchenko JM, Saini M, Valanparambil R, Blum KA, Allen PB, Lechowicz MJ, Romancik JT, Ayers AA, Leal AM, O'Leary CB, Churnetski MC, Baird K, Kives M, Wrammert J, Nooka AK, Koff JL, Dhodapkar MV, Suthar MS, Cohen JB, Ahmed R. Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies. *Cancer Research Communications*. 2022 Dec; 2(12):1684-1692. PubMed PMID: 36644323. PubMed Central PMCID: PMC9833496.
14. Epperla N, Switchenko JM, Bachanova V, Gerson JN, Barta SK, Gordan MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Guo J, Malecek M, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, His ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed mantle cell lymphoma. *Blood Advances*. 2023 Jun 13; 7(11): 2287-2296. PubMed PMID: 36516079. PubMed Central PMCID: PMC10225877.
15. Draper A, Jung E, Cao Y, Atallah RP, Switchenko JM, Kane S, Guadagno J, Jones AT, Brucher E, Alese OB. The impact of poorly differentiated histology on immunotherapy in advanced gastrointestinal cancers. *Oncology*. 2023; 101(4):213-223. PubMed PMID: 36626879.
16. Allen PB, McCook-Veal AA, Switchenko JM, Tarabadkar E, Lechowicz MJ, Baird K, Niyogusaba T, Paulino D. Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study. *Cancer*. 2023 Feb 15; 129(4): 541-550. PubMed PMID: 36523150. PubMed Central PMCID: PMC9852075.
17. McCall NS, Eng TY, Shelton JW, Hanasoge S, Patel PR, Patel AB, McCook-Veal AA, Switchenko JM, Cole TE, Khanna N, Han CH, Gordon AN, Starbuck KD, Remick JS. Incidence and predictors of toxicity in the management of vulvar squamous cell carcinoma treated with radiation therapy. *Gynecologic Oncology Reports*. 2022 Oct 12; 44:101086. PubMed PMID: 36281250. PubMed Central PMCID: PMC9587278.
18. Lipscomb J, Switchenko JM, Flowers CR, Gillespie TW, Wortley PM, Bayakly AR, Almon L, Ward KC. Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are

diagnosed with non-Hodgkin lymphoma: Population-based analyses from the State of Georgia. *Leukemia and Lymphoma*. 2022 Oct 28; 1-10. doi: 10.1080/10428194.2022.2133539. Online ahead of print. PubMed PMID: 36308021.

19. Gross JH, Patel MR, Chan TG, Switchenko JM, Baddour HM, Kaka A, Boyce B, Saba NF, Beitler JJ, El-Deiry M. Oncologic outcomes after clinically node negative salvage laryngectomy. *JAMA Otolaryngology-Head & Neck Surgery*. 2022 Nov 17; e223597. doi: 10.1001/jamaoto.2022.3597. Online ahead of print. PubMed PMID: 36394866. PubMed Central PMCID: PMC9673019.
20. Melucci AD, Chacon AC, Burchard PR, Tsagkalidis V, Casabianca AS, Goyal S, Switchenko JM, Staley CA, Carpizo DR, Shah MM. The impact of carbohydrate antigen 19-9 on survival in patients with clinical stage I and II pancreatic cancer. *Annals of Surgical Oncology*. 2022 Dec; 29(13): 8536-8547. PubMed PMID: 36121582.
21. Kokabi N, Elsayed M, Webster LA, Xing M, Switchenko JM, Chen B, Brandon D, Galt J, Sethi I, Cristescu M, Kappadath C, Schuster DM. Accuracy and safety of scout dose Y90 for radioembolization treatment planning: A prospective single-arm clinical trial. *Journal of Vascular and Interventional Radiology*. 2022 Dec; 33(12): 1578-1587. PubMed PMID: 36075560.
22. Ajay PS, Tsagkalidis V, Casabianca A, Burchard P, Melucci AD, Chacon A, Goyal S, Switchenko JM, Kooby DA, Carpizo DA, Shah MM. A review of hepatic epithelioid hemangioendothelioma – Analyzing patient characteristics and treatment strategies. *Journal of Surgical Oncology*. 2022 Dec; 126(8): 1423-1429. PubMed PMID: 35975699.
23. Sadigh G, Coleman D, Switchenko JM, Hopkins J, Carlos RC. Treatment out-of-pocket cost communication and remote financial navigation in patients with cancer: A feasibility study. *Supportive Care in Cancer*. 2022 Oct; 30(10): 8173-8182. PubMed PMID: 35796885.
24. Moubadder L, Collin L, Nash R, Switchenko JM, Miller-Kleinhenn JM, Gogineni K, Ward KC, McCullough L. Drivers of racial, regional, and socioeconomic disparities in late-stage breast cancer mortality. *Cancer*. 2022 Sep 15; 128(18): 3370-3382. PubMed PMID: 35867419.
25. Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, Qi K, Parisi L, Daly K, Zhu A, Salles G. Treatment outcomes, roles of transplantation or rituximab maintenance in patients with previously untreated mantle cell lymphoma: Results from large real-world cohorts. *Journal of Clinical Oncology*. 2022 Jun 28; JCO210268. doi: 10.1200/JCO.21.02698. Online ahead of print. PubMed PMID: 35763708.
26. Allen PB, Goyal S, Switchenko JM, Tarabaddar E, Pouch S, Parikh P, Palmer A, Martini D, Kim E, Lechowicz MJ. Mitigation strategies among cutaneous T-cell lymphoma patients with positive *Staphylococcus aureus* skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia. *Leukemia and Lymphoma*. 2022 Jun 7; 1-8. doi: 10.1080/10428194.2022.2081324. Online ahead of print. PubMed PMID: 35673767.
27. Collin LJ, Ross-Driscoll K, Nash R, Miller-Kleinhenn JM, Moubadder L, Osborn C, Subhedar P, Gabram-Mendola S, Switchenko JM, Ward KC, McCullough LE. Time to surgical treatment and facility characteristics as potential drivers of racial disparities in breast cancer mortality. *Annals of Surgical Oncology*. 2022 Aug; 29(8): 4728-4738. PubMed PMID: 35435562. PubMed Central PMCID: PMC9703360.
28. Martini D, Goyal S, Switchenko JM, Lechowicz MJ, Allen PB. African American and Caucasian patients with Sézary Syndrome have no differences in outcomes at an ethnically diverse urban medical center. *Leukemia and Lymphoma*. 2022 Sep; 63(9): 2094-2101. PubMed PMID: 35481397.
29. Sadigh G, Coleman D, Lava N, Switchenko JM, Vargas D, Duszak R, Carlos R. Patient-specific out-of-pocket cost communication and remote financial navigation in patients with multiple sclerosis: A randomized controlled feasibility study. *Multiple Sclerosis and Related Disorders*. 2022 Jun; 62: 103797. PubMed PMID: 35429820.
30. Valanparambil RM, Carlisle J, Linderman SL, Akthar A, Millett RL, Lai L, Chang A, McCook-Veal AA, Switchenko JM, Nasti T, Saini M, Weiland A, Steuer C, Nooka AK, Green F, Johns M, O'Brien F,



- Shanmugasundaram U, Zarnitsyna VI, Ahmed H, Nyhoff LE, Mantus G, Behera M, Antia R, Wrammert J, Suthar M, Dhodapkar MV, Ramalingam S, Ahmed R. Antibody response to COVID-19 mRNA vaccine in lung cancer patients after primary immunization and booster: Reactivity to SARS-CoV-2 WT virus and Omicron variant. *Journal of Clinical Oncology*. 2022 Nov 20; 40(33): 3808-3816. PubMed PMID: 35759727. PubMed Central PMCID: PMC9671759.
31. Chang A, Aktar A, Linderman SL, Lai L, Orellana-Noia VM, Valanparambil R, Ahmed H, Zarnitsyna VI, McCook-Veal AA, Switchenko JM, Koff JL, Blum K, Ayers AA, O'Leary C, Churnetski M, Sulaiman S, Kives M, Sheng P, Davis C, Nooka AK, Antia R, Dhodapkar MV, Suthar MS, Cohen JB, Ahmed R. Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. *Journal of Clinical Oncology*. 2022 Sep 10; 40(26): 3020-3031. PubMed PMID: 35436146. PubMed Central PMCID: PMC9470134.
  32. Khalil L, Gao X, Switchenko JM, Alese OB, Akce M, Wu C, Diab M, El-Rayes BF, Shaib WL. Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer. *The Oncologist*. 2022 Sep 2; 27(9): 740-750. PubMed PMID: 35648074. PubMed Central PMCID: PMC9438921.
  33. Reitz AC, Switchenko JM, Gillespie TW. Is Medicaid expansion associated with improved nonmetastatic colon cancer survival? An analysis of the National Cancer Database. *The American Surgeon*. 2022 Feb 25; 31348211050816. doi: 10.1177/00031348211050816. Online ahead of print. PubMed PMID: 35213813; PubMed Central PMCID: PMC9402807.
  34. Nooka AK, Shanmugasundaram U, Cheedarla N, Verkerke H, Edara VV, Valanparambil R, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Azeem M, Manalo J, Switchenko JM, Chang A, Linderman SL, Roback JD, Dhodapkar KM, Ahmed R, Suthar MS, Neish AS, Dhodapkar MV. Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma. *Journal of Clinical Oncology*. 2022 Sep 10; 40(26): 3057-3064. PubMed PMID: 35259002; PubMed Central PMCID: PMC9462534.
  35. Nash R, Russell MC, Miller-Kleinhenz JM, Collin LJ, Ross-Driscoll K, Switchenko JM, McCullough LE. Understanding gastrointestinal cancer mortality disparities in a racially and geographically diverse population. *Cancer Epidemiology*. 2022 Apr; 77: 102110. PubMed PMID: 35144126; PubMed Central PMCID: PMC8923985.
  36. Harkins RA, Patel SP, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum KA, Cashen AF, Casulo C, Friedberg JW, Johnston PB, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan PM, Westin JR, Koff JL, Flowers CR. Improving eligibility criteria for first-line trials for patients with DLBCL using a U.S.-based Delphi-method survey. *Blood Advances*. 2022 May 10; 6(9): 2745-2756. PubMed PMID: 35100356; PubMed Central PMCID: PMC9092417.
  37. Singh V, Gillespie TW, Shteamer JW, Egan K, Zarrabi AJ, Spektor B, Lane O, Curseen K, Tsvetkova M, Beumer JH, Switchenko JM, Sniecinski R, Harvey RD. A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain. *Pharmacotherapy*. 2022 Apr; 42(4): 298-310. PubMed PMID: 35146776; PubMed Central PMCID: PMC9118341.
  38. Hansen T, Gangal A, Hijab E, Barrett D, Yeung H, Cao Y, Switchenko JM, Blalock TW. Postoperative surgical site infection rate in patients with diabetes following Mohs micrographic surgery: A retrospective analysis. *Journal of the European Academy of Dermatology and Venereology*. 2022 Jun; 36(6): 927-931. PubMed PMID: 35122334.
  39. Burchard PR, Ullman NA, Chacon AC, Melucci A, Tsagkalidis V, Casabianca AS, Reitz AC, Swift DA, Goyal S, Switchenko JM, Kooby DA, Carpizo DR, Shah MM. Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma. *Journal of Surgical Oncology*. 2022 Apr; 125(5): 856-864. PubMed PMID: 34994405; PubMed Central PMCID: PMC9082653.
  40. Min TL, Xu L, Choi JD, Hu R, Allen JW, Reeves C, Hsu D, Duscak R, Switchenko JM, Sadigh G. COVID-19 pandemic-associated changes in the acuity of brain MRI imaging findings: A secondary analysis of reports using

natural language processing. *Current Problems in Diagnostic Radiology*. Jul-Aug 2022; 51(4): 529-533 PubMed PMID: 34955284; PubMed Central PMCID: PMC8636309.

41. Blee SM, Facdol J, Dixon M, Master V, Switchenko JM, Pentz RD. Dissemination of validated health literacy videos: A tailored approach. *Cancer Medicine*. 2022 Apr; 11(7): 1678-1687. PubMed PMID: 35107221; PubMed Central PMCID: PMC8986138.
42. Janopaul-Naylor, JR, Beck LE, Roberts SE, Shu HK, Kesarwala AH, Lin J, Switchenko JM, Torres MA. Race, ethnicity, and sex among senior faculty in radiation oncology from 2000 to 2019. *JAMA Network Open*. 2022 Jan 4; 5(1): e2142720. PubMed PMID: 35015068; PubMed Central PMCID: PMC8753507.
43. Dhere VR, Escott CE, Switchenko JM, Bell JP, McDonald MW, Stokes WA, Hess CB, Magliocca KR, Boyce BJ, Kaka AS, Saba NF, Steuer CE, Shin DM, Xiao C, Ottenstein L, Patel MR, Beitler JJ. The omission of intentional primary site radiation following Transoral Robotic Surgery (TORS) in 59 patients: No local-regional failures. *Head & Neck*. 2022 Feb; 44(2): 382-390. PubMed PMID: 34850994; PubMed Central PMCID: PMC8766901.
44. Bidot S, Monsrud A, Kline M, Speak A, Bilen MA, Switchenko JM, Zhang Y, Gerges AG, Farhat G, Dent EA, Master V, Tinsley M, Harik LR. Risk stratification of prostatic adenocarcinoma metastatic to the lymph nodes. *Archives of Pathology and Laboratory Medicine*. 2022 Nov 1; 146(11): 1345-1352. PubMed PMID: 35142822; PubMed Central PMCID: PMC9363522.
45. Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, Zhong J, Yushak ML, Harvey RD, Paulos CM, Lawson DH, Khan MK, Kudchadkar RR, Buchwald ZS. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): A propensity score-matched analysis of a single-centre, longitudinal study. *Lancet Oncology*. 2021 Dec; 22(12): 1777-1786. PubMed PMID: 34780711.
46. Hess C, Eng TY, Nasti TH, Dhere VR, Kleber TJ, Switchenko JM, Weinberg BD, Rouphael N, Tian S, Rudra S, Taverna LS, Daisson AP, Ahmed R. Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesivir. *Radiotherapy and Oncology*. 2021 Dec; 165: 20-31. PubMed PMID: 34653525. PubMed Central PMCID: PMC8511870.
47. Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek M-K, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik JT, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski AJ, Ayers EC, Landsburg DJ, Echalié B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. *Blood*. 2022 Jan 20; 139(3): 413-423. PubMed PMID: 34570876; PubMed Central PMCID: PMC8777199.
48. Campbell GP, Dixon MD, Lohani M, Cook JW, Hianik RS, Thomson MC, Abernethy ER, Lewis C, Switchenko JM, Harvey RD, Pentz RD. Therapeutic misconception about research procedures: Does a simple information chart improve understanding? *Ethics & Human Research*. 2022 Mar; 44(2): 18-25. PubMed PMID: 35218599; PubMed Central PMCID: PMC9069479.
49. Allaw MB, Switchenko JM, Khalil L, Wu C, Alese OB, Akce M, Draper A, Jones AT, El-Rayes BF, Shaib WL. Comparing somatostatin analogs in the treatment of advanced gastroenteropancreatic neuroendocrine tumors. *Oncology*. 2022; 100(3): 131-139. PubMed PMID: 35078191; PubMed Central PMCID: PMC9052205.
50. Blee S, Rosenberg B, Switchenko JM, Hianik R, Thomson MC, Dixon M, Bilen MA, Pentz RD. Understanding immunotherapy terminology: An analysis of provider-patient conversations. *Immunomedicine*. 2021 Dec; 1(2): e1028. PubMed PMID: 34901734; PubMed Central PMCID: PMC8659848.
51. Syed Y, Jiang C, Switchenko JM, Kirmani K, Dabaja B, Kelsey C, Khan MK. Improved progression-free survival for bulky and non-bulky advanced stage diffuse large B-cell lymphoma with consolidative radiation therapy: A bi-

institutional analysis. *Cureus*. 2021 Aug 11; 13(8): e17107. PubMed PMID: 34527492; PubMed Central PMCID: PMC8432970.

52. Blee SM, Shah RP, Pinheiro AP, Switchenko JM, Dixon M, Owonikoko TK, Szabo SM, Pentz RD. Physician communication and patient understanding of molecular testing terminology. *The Oncologist*. 2021 Nov; 26(11): 934-940. PubMed PMID: 34369626. PubMed Central PMCID: PMC8571766.
53. Karmali R, Switchenko JM, Goyal S, Bachanova V, Gerson J, Barta SK, Danilov AV, Grover NS, Epperla N, Burkart M, Sawalha Y, Ghosh N, Bond DA, Maddocks KJ, Badar T, Fenske T, Guo J, Malecek M, Martin P, Cohen JB. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. *American Journal of Hematology*. 2021 Nov 1; 96(11): 1374-1384. PubMed PMID: 34324220. PubMed Central PMCID: PMC8511300.
54. Abugideiri M, Janopaul-Naylor J, Switchenko JM, Tian S, Read W, Oskouei S, Reimer N, Behera M, Monson D, Landry J, Godette KD, Patel PR. Impact of metastasectomy and aggressive local therapy in newly diagnosed metastatic soft tissue sarcoma: an analysis of the NCDB. *Annals of Surgical Oncology*. 2022 Jan; 29(1): 649-659. PubMed PMID: 34272614. PubMed Central PMCID: PMC8688266.
55. Miller-Kleinhenz J, Collin LJ, Seidel R, Reddy A, Gogineni K, Nash R, Switchenko JM, McCullough LE. Racial disparities in diagnostic delay among women with breast cancer. *Journal of the American College of Radiology*. 2021 Oct; 18(10): 1384-1393. PubMed PMID: 34280379. PubMed Central PMCID: PMC8492512.
56. Sadigh G, Switchenko JM, Elchoufi D, Meisel J, Bilen AM, Lawson D, El-Rayes B, Carlos R. Correlates of financial toxicity in adult cancer patients and their informal caregivers. *Supportive Care in Cancer*. 2022 Jan; 30(1): 217-225. PubMed PMID: 34255179. PubMed Central PMCID: PMC8639637.
57. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bechanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek M, Khal BS, Flowers CR, Blum KA, Cohen JB. Early relapse identifies MCL patients with inferior survival after both intensive or less intensive frontline therapy. *Blood Advances*. 2021 Dec 14; 5(23): 5179-5189. PubMed PMID: 3451661. PubMed Central PMCID: PMC9153047.
58. Sibold C, Thomson MC, Hianik R, Sumrall B, Dillmon M, Simmons J, Abernathy ER, Campbell GP, Switchenko JM, Dixon MD, Pentz RD. Videos improve patient understanding of chemotherapy terminology in a rural setting. *Cancer*. 2021 Nov 1; 127(21): 4015-4021. PubMed PMID: 34289098. PubMed Central PMCID: PMC8516682.
59. Taylor M, Switchenko JM, Patel MR, McDonald M, Steuer C, Beitler JJ, Shin DM, Saba NF. Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population – A SEER based analysis from 2000-2016. *Cancer Medicine*. 2021 Sep; 10(17): 6070-6077. PubMed PMID: 34288563. PubMed Central PMCID: PMC8419769.
60. Hianik RS, Owonikoko TK, Switchenko JM, Dixon MD, Shaib WL, Pentz RD. Evaluating the impact of the Patient Preference Assessment Tool on clinicians' recommendations for phase I oncology clinical trials. *Psycho-Oncology*. 2021 Oct; 30(10): 1739-1744. Online ahead of print. PubMed PMID: 34038982; PubMed Central PMCID: PMC8497404.
61. Switchenko JM, Roy SL, Munoz F, Lopez G, Rivera JG, Cuellar VM, Juliao P, Lopez B, Thornton A, Patel JC, Alvarez M, Reyes L, Derado G, Arvelo W, Lindblade KA. Non-coverage assessment of aerial photographs used to generate a sampling frame for a cross-sectional survey in Nueva Santa Rosa, Guatemala. *Global Health Reports*. 2021; 5:e2021056. doi: 10.29392/001c.24585.
62. Abernathy E, Campbell G, Hianik R, Thompson MC, Blee S, Sibold C, Dixon M, Switchenko JM, Pentz RD. Reassessing the measurement and presence of therapeutic misconception in a Phase I setting. *Cancer*. 2021 Oct 15; 127(20): 3794-3800. PubMed PMID: 34161615.

63. Sadigh G, Switchenko JM, Lava N, Duscak R, Krupinski EA, Meltzer CC, Carlos RC. Longitudinal changes of financial hardship in patients with multiple sclerosis. *Multiple Sclerosis and Related Disorders*. 2021 Aug; 53:103037. PubMed PMID: 34077829.
64. Marks JA, Switchenko JM, Martini D, Tarabackar ES, Khan MK, Lechowicz MJ, Allen PB. T-cell receptor gene rearrangement clonality, flow cytometry status, and associated outcomes in early-stage CTCL. *JAMA Dermatology*. 2021 Aug 1; 157(8): 954-962. PubMed PMID: 34190977. PubMed Central PMCID: PMC8246334.
65. Shanmugasundaram K, Goyal S, Switchenko JM, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB. Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. *European Journal of Haematology*. 2021 Sep; 107(3): 301-310. PubMed PMID: 33973276; PubMed Central PMCID: PMC8338766.
66. Patel MR, Ottenstein L, Ryan M, Farrell A, Studer M, Baddour H, Magliocca K, Griffith C, Stokes W, Switchenko JM, Aiken A, El-Deiry M, Solares C, Steuer C, Saba N, Beitler J. TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS. *Oral Oncology*. 2021 Jun; 117: 105294. PubMed PMID: 33878679; PubMed Central PMCID: PMC8281337.
67. Jiang C, Kleber T, Switchenko JM, Khan MK. Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases. *Radiation Oncology*. 2021 Feb 8; 16(1): 31. PubMed PMID: 33557890. PubMed Central PMCID: PMC7871629.
68. Ottenstein L, Cornett H, Nathan M, Thomas S, Switchenko JM, Barrett T, Brinkman M, Kaka AS, Boyce BJ, Saba NF, Aiken AH, El-Deiry M, Beitler JJ, Patel MR. Characterizing post-operative physiologic swallow function following transoral robotic surgery (TORS) for early stage tonsil, base of tongue, and unknown primary HPV-associated squamous cell carcinoma. *Head & Neck*. 2021 May; 43(5): 1629-1640. PubMed PMID: 33547716. PubMed Central PMCID: PMC8046724.
69. Hess CB, Buchwald Z, Stokes WA, Nasti T, Switchenko JM, Weinberg B, Rouphael N, Steinberg JP, Godette K, Murphy DJ, Ahmed R, Curran WJ, Khan MK. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia. *International Journal of Radiation Oncology, Biology & Physics*. 2020 Dec 1;108(5):1401. PubMed PMID: 33427662. PubMed Central PMCID: PMC7671923.
70. Collin LJ, Yan M, Jiang R, Gogineni K, Subhedar P, Ward K, Switchenko JM, Lipscomb J, Miller-Kleinhenz J, Lin J, McCullough LE. Receipt of guideline-concordant care does not explain breast cancer mortality disparities by race in metropolitan Atlanta. *Journal of the National Comprehensive Cancer Network*. 2021 Aug 16; jncn20258. doi: 10.6004/jncn.2020.7694. Online ahead of print. PubMed PMID: 34399407. PubMed Central PMCID: PMC8847540.
71. Marks JA, Switchenko JM, Steuer C, Ryan M, Patel MR, McDonald MM, Higgins K, Beitler JJ, Shin DM, Gillespie TW, Saba NF. Socioeconomic factors influence the impact of tumor HPV status on outcome of patients with OPSCC. *JCO – Oncology Practice*. 2021 Mar; 17(3): e313-e322. PubMed PMID: 33434083. PubMed Central PMCID: PMC8258012.
72. Patel SA, Switchenko JM, Kishan AU, Jani AB, Royce TJ, Fischer-Valuck BW. Stereotactic body radiation therapy use for high risk prostate cancer in the United States. *Prostate Cancer & Prostatic Diseases*. 2021 Jun; 24(2): 578-581. PubMed PMID: 33188271. PubMed Central PMCID: PMC8116349.
73. Krummel DA, Nasti TH, Kaluzova M, Kallay L, Bhattacharyya D, Melms JC, Izar B, Xu M, Burnham A, Ahmed T, Li G, Lawson D, Kowalski J, Cao Y, Switchenko JM, Ionascu D, Cook JM, Medvedovic M, Khan MK, Sengupta S. Melanoma cell intrinsic GABAA receptor enhancement potentiates radiation and immune checkpoint inhibitor response by promoting direct and T cell-mediated antitumor activity. *International Journal of Radiation Oncology, Biology, Physics*. 2021 Mar 15; 109(4):1040-1053. PubMed PMID: 33289666. PubMed Central PMCID: PMC8329598.

74. Meltzer RS, Kooby DA, Switchenko JM, Datta J, Carpizo DR, Maithel SK, Shah MM. Does major pancreatic surgery have value in nonagenarians with pancreatic cancer? *Journal of Surgical Oncology*. 2021 Apr; 28(4): 2265-2272. PubMed PMID: 33141373; PubMed Central PMCID: PMC7940572.
75. Collin LJ, Gaglioti AH, Beyer KM, Zhou Y, Moore MA, Nash R, Switchenko JM, Miller-Kleinhenz JM, Ward KC, McCullough LE. Neighborhood-level redlining and lending bias are associated with breast cancer mortality in a large and diverse metropolitan area. *Cancer Epidemiology, Biomarkers & Prevention*. 2021 Jan; 30(1): 53-60. PubMed PMID: 32986274. PubMed Central PMCID: PMC7855192.
76. Ross JL, Chen Z, Herting CJ, Szulzewsky F, Grabovska Y, Puigdelloses M, Monterroza L, Switchenko JM, Wadhvani NR, Cimino PJ, Mackay A, Jones C, Read R, MacDonald T, Schniederjan M, Becher OJ, Hambardzumyan D. Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma. *Brain*. 2021 Feb 12; 144(1): 53-69. PubMed PMID: 33300045. PubMed Central PMCID: PMC7954387.
77. Patel SA, Switchenko JM, Fischer-Valuck B, Zhang C, Rose BS, Chen RC, Jani AB, Royce TJ. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer. *Radiation Oncology*. 2020 Sep 15; 15(1): 217. PubMed PMID: 32933541. PubMed Central PMCID: PMC7493337.
78. Sadigh G, Lava N, Switchenko JM, Duscak RD, Krupinski EA, Meltzer C, Hughes D, Carlos RC. Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence. *Multiple Sclerosis*. 2021 Mar; 27(3): 453-464. PubMed PMID: 32808562.
79. Tewkesbury G, Carlos RC, Duszak R, Krupinski EA, Switchenko JM, Meltzer C, Lava N, Sadigh G. Perceptions and experiences of multiple sclerosis patients regarding out-of-pocket costs of care discussion. *Multiple Sclerosis and Related Disorders*. 2020 Oct; 45:102344. PMID: 32622297.
80. Hess CB, Buchwald ZS, Stokes W, Switchenko JM, Nasti TH, Weinberg BD, Steinberg JP, Godetter KD, Ahmed R, Curran WJ, Khan MK. Low dose whole-lung radiation for COVID-19 pneumonia. Planned day 7 interim analysis of a registered clinical trial. *Cancer*. 2020 Dec 1; 126(23): 5109-5113. PubMed PMID: 32986274. PubMed Central PMCID: PMC7748390.
81. Kudelka MR, Switchenko JM, Lechowicz MJ, Esiashvili N, Flowers CR, Khan MK, Allen PB. Maintenance therapy in cutaneous T-cell lymphoma after total skin electron irradiation: Evidence for improved overall survival with ultraviolet therapy. *Clinical Lymphoma, Myeloma, and Leukemia*. 2020 Nov; 20(11): 757-767. PubMed PMID: 32703750. PubMed Central PMCID: PMC9126313.
82. Royce TJ, Switchenko JM, Zhang C, Spratt DE, Chen RC, Jani AB, Patel SA. Low utilization of androgen deprivation therapy among men receiving stereotactic body radiotherapy for localized prostate cancer in the United States. *European Urology Oncology*. 2020 Jul 2; S2588-9311(20)30084-5. doi: 10.1016/j.euro.2020.06.006. Online ahead of print. PubMed PMID: 32624420. PubMed Central PMCID: PMC7775872.
83. Shaib WL, Zakka K, Shahin AA, Yared F, Switchenko JM, Wu C, Akce M, Alese OB, Patel PR, McDonald M, El-Rayes BF. Radiation as a single-modality treatment in localized pancreatic cancer. *Pancreas*. 2020 Jul; 49(6): 822-829. PubMed PMID: 32541638. PubMed Central PMCID: PMC8011591.
84. Eng NL, Mustin DE, Lovasik BP, Turgeon MK, Gamoba AC, Shah MM, Cardona K, Sarmiento JM, Russell MC, Maithel SK, Switchenko JM, Kooby DA. Relationship of cancer diagnosis to complications following pancreatoduodenectomy for duodenal adenoma. *Annals of Surgical Oncology*. 2021 Feb; 28(2): 1097-1105. PubMed PMID: 32691338. PubMed Central PMCID: PMC7856223.
85. Jella KK, Nasti TH, Li Z, Lawson D, Switchenko JM, Ahmed R, Dynan WS, Khan MK. Exosome-containing preparations from post-irradiated mouse melanoma cells delay melanoma growth in vivo by a natural killer cell-dependent mechanism. *International Journal of Radiation Oncology, Biology, and Physics*. 2020 Sep 1; 108(1):104-114. PubMed PMID: 32561502. PubMed Central PMCID: PMC7751005.

86. Allen PB, Switchenko JM, Ayer A, Kim E, Lechowicz MJ. Risk factors for bacteremia and survival in patients with cutaneous T-cell lymphoma (CTCL). *Leukemia & Lymphoma*. 2020 Nov; 61(11): 2652-2658. PubMed PMID: 32558600. PubMed Central PMCID: PMC7741151.
87. Turgeon MK, Gamboa AC, Rupji M, Lee RM, Switchenko JM, El-Rayes BF, Russell MC, Cardona K, Kooby DA, Staley CA, Maithel SK, Shah MM. Should signet ring cell histology alter the treatment approach for clinical stage I gastric cancer? *Annals of Surgical Oncology*. 2021 Jan; 28(1): 97-105. PubMed PMID: 32524459. PubMed Central PMCID: PMC7725995.
88. Gamboa AC, Meyer BI, Switchenko JM, Rupji M, Lee RM, Turgeon MK, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma? *Journal of Surgical Oncology*. 2020 Sep; 122(3): 412-421. PubMed PMID: 32462769. PubMed Central PMCID: PMC7396283.
89. Escott C, Zaenger D, Lin J, Switchenko JM, Meisel J, Subhedar P, Arciero C, Torres M, Patel P. The influence of histologic grade on outcomes of elderly women with early stage breast cancer treated with breast conserving surgery with or without radiotherapy. *Clinical Breast Cancer*. 2020 Dec; 20(6):e701-e710. PubMed PMID: 32665190. PubMed Central PMCID: PMC8496963.
90. Gamboa AC, Rupji M, Switchenko JM, Lee RM, Turgeon MK, Meyer BI, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. Optimal timing and treatment strategy for pancreatic cancer. *Journal of Surgical Oncology*. 2020 Sep; 122(3): 457-468. PubMed PMID: 32470166. PubMed Central PMCID: PMC7396281.
91. Baddour HM, Ochsner MC, Patel MR, Switchenko JM, Beitler JJ, Magliocca K, Baugnon KL, Solares CA, Steuer CE, El-Deiry MW. Surgical resection is justifiable for oral T4b squamous cell cancers with masticator space invasion. *Laryngoscope*. 2021 Feb; 131(2): E466-E472. PubMed PMID: 32460370. PubMed Central PMCID: PMC7704866.
92. Buchwald ZS, Tian S, Rossi M, Smith GH, Switchenko JM, Hauenstein JE, Moreno CS, Press RH, Prabhu RS, Zhong J, Saxe DF, Neil SG, Olson JJ, Crocker IR, Curran WJ, Shu HG. Genomic copy number variation correlates with survival outcomes in WHO grade IV glioma. *Scientific Reports*. 2020 Apr; 10(1): 7355. PubMed PMID: 32355162. PubMed Central PMCID: PMC7192941.
93. Lee MJ, Koff JL, Switchenko JM, Jhaney CI, Patel SP, Harkins A, Dave SS, Flowers CR. Genome-defined African ancestry is associated with distinct mutations and survival in diffuse large B-cell lymphoma. *Cancer*. 2020 Aug 1; 126(15): 3493-3503. PubMed PMID: 32469082. PubMed Central PMCID: PMC7494053.
94. Tian S, Switchenko JM, Buchwald ZS, Patel PR, Shelton JW, Kahn SE, Pillai RN, Steuer CE, Owonikoko TK, Behera M, Curran WJ, Higgins KA. Lung stereotactic body radiotherapy and concurrent immunotherapy: A multi-center safety and toxicity analysis. *International Journal of Radiation Oncology, Biology, and Physics*. 2020 Sep 1; 108(1):304-313. PubMed PMID: 31982496. PubMed Central PMCID: PMC7747230.
95. Bean MB, Switchenko JM, Steuer CE, Patel M, Higgins K, McDonald M, Chen GZ, Beitler JJ, Shin DM, Gillespie TW, Saba NF. Demographic and socioeconomic factors associated with metastases at presentation in HPV-related squamous cell carcinoma of the head and neck: An NCDB analysis. *JCO Oncology Practice*. 2020 Jun; 16(6): e476-e487. PubMed PMID: 32048934. PubMed Central PMCID: PMC8462628.
96. Switchenko JM, Jennings J, Waller L. Exploring spatially varying demographic associations with gonorrhea incidence in Baltimore, MD, 2002-2005. *Journal of Geographical Systems*. 2020 Apr; 22: 201-216. PubMed PMID: PubMed Central PMCID: PMC7943037.
97. Tian S, Switchenko JM, Fei T, Press RH, Abugideiri M, Saba NF, Owonikoko TK, Chen AY, Beitler JJ, Curran WJ, Gillespie TW, Higgins KA. Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: A propensity score matched analysis with multiple subgroups. *Head & Neck*. 2020 Apr; 42(4): 678-687. PubMed PMID: 31845469. PubMed Central PMCID: PMC7082181.

98. Lipscomb J, Switchenko JM, Flowers CR, Gillespie TW, Wortley P, Bayakly AR, Almon L, Fernando R, Ward KC. Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: A population-based investigation in the state of Georgia. *Leukemia & Lymphoma*. 2020 Apr; 61(4): 896-904. PubMed PMID: 31852329. PubMed Central PMCID: PMC7082188.
99. Parent EE, Sethi I, Nye J, Holder C, Olson JJ, Switchenko JM, Tade F, Akin-Akintayo OO, Ojo OA, Akintayo A, Schuster DM. <sup>82</sup>Rubidium chloride PET discrimination of recurrent intracranial malignancy from radiation necrosis. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*. 2022 Mar; 66(1): 74-81. PubMed PMID: 31820882. PubMed Central PMCID: PMC7958885.
100. Clough L, Bayakly AR, Ward K, Khan MK, Chen SC, Lechowicz MJ, Flowers CR, Allen PB, Switchenko JM. Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the State of Georgia. *Cancer*. 2020 Apr 15; 126(8): 1700-1707. PubMed PMID: 31943154. PubMed Central PMCID: PMC7328827.
101. Tanenbaum DG, Buchwald ZS, Jhaveri J, Schreibmann E, Switchenko JM, Prabhu RS, Chowdhary M, Abugidieri M, Eaton B, Kahn SE, Olson JJ, Shu HG, Crocker IR, Curran WJ, Patel KR. Dosimetric factors related to radiation necrosis after five fraction radiosurgery for resected brain metastases. *Practical Radiation Oncology*. Jan-Feb 2020; 10(1):36-43. PubMed PMID: 31586666. PubMed Central PMCID: PMC6958701.
102. Ethun CG, Lopez-Aguilar AG, Switchenko JM, Gillespie TW, Delman KA, Staley CA, Maithel SK, Cardona K. The prognostic value of lymphovascular invasion in truncal and extremity soft tissue sarcomas: An analysis from the National Cancer Data Base. *Annals of Surgical Oncology*. 2019 Dec; 26(13): 4723-4729. PubMed PMID: 31502023. PubMed Central PMCID: PMC6958703.
103. Kaffes I, Szulzewsky F, Chen Z, Herting CJ, Velazquez Vega JE, Shelton J, Switchenko JM, Ross JL, McSwain LF, Huse J, Westermarck B, Nelander S, Forsberg-Nilsson K, Uhrbom L, Holland EC, Kettermann H, Brat DJ, Hambardzumyan D. Human mesenchymal glioblastomas are characterized by an increased immune cell infiltration compared to proneural and classical tumors. *OncImmunity*. 2019 Aug 22; 8(11): e1655360. PubMed PMID: 31646100. PubMed Central PMCID: PMC6791439.
104. Switchenko JM, Heeke AL, Pan TC, Read WL. The use of a predictive statistical model to make a virtual control arm for a clinical trial. *PLoS One*. 2019 Sep 4; 14(9): e0221336. PubMed PMID: 31483824. PubMed Central PMCID: PMC6726216.
105. Gamboa AC, Ethun CG, Zaidi MY, Switchenko JM, Lipscomb J, Tran TB, Poultsides G, Grignol V, Howard JH, Bedi M, Gamblin TC, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Cullinan D, Fields RC, Oskoue SV, Monson DK, Reimer NB, Maithel SK, Delman KA, Cardona K. Lung surveillance strategy for high-grade soft tissue sarcomas: Chest X-ray or CT scan? *Journal of the American College of Surgeons*. 2019 Nov; 229(5): 449-457. PubMed PMID: 31377411. PubMed Central PMCID: PMC6815708.
106. Lee RM, Switchenko JM, Ho TB, Arciero CA, Bhawe MA, Subhedar PD. Is routine recurrence score testing in patients older than 70 years of age warranted? An evaluation of the National Cancer Database after TAILORx. *Annals of Surgical oncology*. 2019 Oct; 26(10): 3152-3158. PubMed PMID: 31342377. PubMed Central PMCID: PMC6736707.
107. Zaidi MY, Lopez-Aguilar AG, Switchenko JM, Lipscomb J, Andreasi V, Partelli S, Gamboa AC, Lee RM, Poultsides GA, Dillhoff M, Rocha FG, Idress K, Cho CS, Weber SM, Fields RC, Staley CA, Falconi M, Maithel SK. A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: An international study of 1006 patients. *Annals of Surgery*. 2019 Sep; 270(3): 422-433. PubMed PMID: 31283562. PubMed Central PMCID: PMC6697205.
108. Gamboa AC, Zaidi MY, Lee RM, Speegle S, Switchenko JM, Lipscomb J, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Dessureault S, Veerapong J, Baumgartner JM, Clarke C, Gamlin TC, Patel SH, Lee TC, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Johnston FM, Greer J, Russell MC, Staley

- CA, Maithel SK. Optimal surveillance frequency after CRS/HIPEC for appendiceal and colorectal neoplasms: A multi-institutional analysis of the US HIPEC Collaborative. *Annals of Surgical Oncology*. 2020 Jan; 27(1): 134-146. PubMed PMID: 31243668. PubMed Central PMCID: PMC6925634.
109. Goldstein JS, Switchenko JM, Behera M, Flowers CR, Koff JL. Insurance status impacts overall survival in Burkitt lymphoma. *Leukemia & Lymphoma*. 2019 Dec; 60(13): 3225-3234. PubMed PMID: 31274033. PubMed Central PMCID: PMC6923579.
  110. Liu Y, Nickleach DC, Switchenko JM, Zhang C, Kowalski J. Carrying out streamlined routine data analyses with reports for observational studies: Introduction to a series of generic SAS macros. *F1000 Research*. 2018 Dec 19 [revised 2019 Jun 5];7:1955. doi: 10.12688/f1000research.16866.2. eCollection 2018. PubMed PMID: 31231506. PubMed Central PMCID: PMC6567291.
  111. Tian S, Ferris MJ, Switchenko JM, Magliocca KR, Cassidy RJ, Kendi AT, Tanenbaum DG, Aiken AH, Baugnon KL, Hudgins PA, Patel MR, Saba NF, Curran WJ, Beitler JJ. Prognostic value of radiographically-defined extracapsular extension is modulated in HPV-associated in locally advanced oropharyngeal carcinoma. *Head & Neck*. 2019 Sep; 41(9): 3056-3063. PubMed PMID: 31046181. PubMed Central PMCID: PMC6707079.
  112. Pentz RD, Lohani M, Hayban M, Switchenko JM, Dixon MD, Jani AB, DeFeo RJ, Ofloff GM, Master VA. Videos improve patient understanding of misunderstood chemotherapy terminology. *Cancer*. 2019 Nov 15; 125(22): 4011-4018. PubMed PMID: 31418849. PubMed Central PMCID: PMC6986301.
  113. Ferris MJ, Sykes K, Switchenko JM, Kayode OA, Wolf J, Dang Q, Press RH, Curran WJ, Higgins KA. Sparing cardiac substructures with optimized volumetric modulated arc therapy and intensity-modulated proton therapy in thoracic radiation for locally advanced non-small cell lung cancer. *Practical Radiation Oncology*. 2019 Sep - Oct; 9(5): e473-e481. PubMed PMID: 31077884. PubMed Central PMCID: PMC6718306.
  114. McDaniels BA, Hianik RS, Bellcross C, Shaib W, Switchenko JM, Dixon MD, Meisel JL, Gogineni K, Pentz RD. The impact of genetic counseling educational tools on patients' knowledge of molecular testing terminology. *Journal of Cancer Education*. 2020 Oct; 35(5): 864-870. PubMed PMID: 31062281. PubMed Central PMCID: PMC6834865.
  115. Tian S, Switchenko JM, Jhaveri J, Cassidy RJ, Ferris MJ, Press RH, Pfister NT, Patel MR, Saba NF, McDonald MW, Higgins KA, Yu DS, Curran WJ, Gillespie TW, Beitler JJ. Survival Outcomes by High-Risk HPV Status in Non-Oropharynx Head and Neck Squamous Cell Carcinomas: A Propensity-Scored Analysis of the National Cancer Data Base. *Cancer*. 2019 Aug 15; 125(16): 2782-2793. PubMed PMID: 31012957. PubMed Central PMCID: PMC6663628.
  116. Abugideiri M, Schreiber E, Switchenko J, McDonald M, Beitler J, Curran W, Bruner D, Patel P, Tigeneh W, Mijena M, Dhabaan A, Esiashvili N, Liu T, Ali A. A prospective international pilot study evaluating the efficacy of a self-guided contouring teaching module with integrated feedback for transitioning from 2-D to 3-D treatment planning. *Journal of Global Oncology*. 2019 May; 5: 1-16. PubMed PMID: 31082303. PubMed Central PMCID: PMC6550062.
  117. Teras LR, Diver WR, Deubler EL, Krewski D, Flowers CR, Switchenko JM, Gapstur SM. Population-based, residential, ambient benzene exposure in the United States and subsequent risk of hematologic malignancies. *International Journal of Cancer*. 2019 Nov 15; 145(10): 2647-2660. PubMed PMID: 30737780.
  118. Chowdhary M, Switchenko JM, Sen N, Chhabra AM, Katz LM, Jegadeesh N, Barry PN, Wang D, Royce T, Curran WJ, Vapiwala N, Wilson LD, Abrams RA, Marwaha G, Patel KR. The impact of graduates' job preferences on the current radiation oncology job market. *International Journal of Radiation Oncology, Biology, and Physics*. 2019 May 1; 104(1): 27-32. PubMed PMID: 30583039. PubMed Central PMCID: PMC6985896.
  119. Tian S, Switchenko JM, Cassidy RJ, Escott CE, Castillo R, Patel PR, Curran WJ, Higgins KA. Predictors of pneumonitis-free survival following lung stereotactic body radiation therapy. *Translational Lung Cancer Research*. 2019 Feb; 8(1): 15-23. PubMed PMID: 30788231. PubMed Central PMCID: PMC6351398.



120. Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD. Academic oncology clinicians' understanding of biosimilars and criteria important to biosimilar prescription. *Therapeutic Advances in Medical Oncology*. 2019 Jan; 11:1758835918818335. PubMed PMID: 30671144. PubMed Central PMCID: PMC6327341.
121. Morgan TM, Zaenger D, Switchenko JM, Eaton BR, Ali AN, Corcker IR, Shu HG. Fractionated radiotherapy is associated with lower rates of treatment-related edema than stereotactic radiosurgery in magnetic imaging-defined meningiomas. *World Neurosurgery*. 2019 Jan; 121: c640-e646. PubMed PMID: 30292026. PubMed Central PMCID: PMC6407415.
122. Beitler JJ, Switchenko JM, Dignam JJ, Higgins KA, Eaton BR, Cassidy RJ, El-Deiry MW, Patel MR, Saba NF, Steuer CE, Magliocca KR, Xiao C, Hudgins PA, Aiken AH, Le QT, Curran WJ. P16 status, smoking, age and risk of distant metastases in patients with squamous cell cancer of the oropharynx. *Cancer*. 2019 Mar; 125(5): 704-711. PubMed PMID: 30548235. PubMed Central PMCID: PMC6463275.
123. Shaib WL, Narayan AS, Switchenko JM, Kane S, Wu C, Akce M, Alese OB, Patel P, Maitel SK, Sarmiento J, Kooby D, El-Rayes BF. Role of adjuvant therapy in resected Stage IA sub-centimeter (T1b/T1b) pancreatic cancer. *Cancer*. 2019 Jan; 125(1): 57-67. PubMed PMID: 30457666. PubMed Central PMCID: PMC6309502.
124. Morgan TM, Wang X, Qian X, Switchenko JM, Nie S, Patel KR, Cassidy RJ, Shin DM, Beitler JJ. Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes. *Clinical and Translational Oncology*. 2019 Mar; 21(3): 342-347. PubMed PMID: 30084036. PubMed Central PMCID: PMC6363890.
125. Zhong J, Switchenko JM, Jegadeesh N, Cassidy RJ, Gillespie T, Master V, Nieh P, Alemozaffar M, Kucuk O, Carthon B, Filson C, Bilen MA, Jani AB. Comparison of outcomes in patients with muscle invasive bladder cancer treated with radical cystectomy versus bladder-preservation. *American Journal of Clinical Oncology*. 2019 Jan; 42(1): 36-41. PubMed PMID: 29912804. PubMed Central PMCID: PMC6295350.
126. Cassidy RJ, Switchenko JM, El-Deiry MW, Belcher RH, Zhong J, Steuer CE, Saba NF, McDonald MW, Yu D, Gillespie TW, Beitler JJ. Disparities in postoperative therapy for salivary gland adenoid cystic carcinomas. *Laryngoscope*. 2019 Feb; 129(2): 377-386. PubMed PMID: 30194768. PubMed Central PMCID: PMC6344280.
127. Schlafstein AJ, Withers AE, Rudra S, Danelia D, Switchenko JM, Mister D, Harari S, Ehdaivand S, Li X, Torres MA, Yu DS. CDK9 expression is a favorable prognostic biomarker in breast cancer patients who fail to achieve pathologic complete response after neoadjuvant chemotherapy. *International Journal of Breast Cancer*. 2018 Oct; 2018:6945129. PubMed PMID: 30405916. PubMed Central PMCID: PMC6204190.
128. Cassidy RJ, Switchenko JM, Yushak ML, Madden N, Khan MK, Monson DK, Beitler JJ, Landry JC, Godette KD, Gillespie TW, Patel KR. The importance of surgery in scalp angiosarcomas. *Surgical Oncology*. 2018 Dec; 27(4): A3-A8. PubMed PMID: 30237037. PubMed Central PMCID: PMC6261443.
129. Chowdhary M, Switchenko JM, Press RH, Jhaveri J, Blumenfeld P, Marwaha G, Diaz A, Wang D, Abrams RA, Olson J, Shu HG. Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. *Neuro-oncology*. 2018 Sep; 139(3): 689-697. PubMed PMID: 29846893. PubMed Central PMCID: PMC6126986.
130. Ferris MJ, Tian S, Switchenko JM, Madden NA, Eaton BR, Esiashvili N. Musculoskeletal outcomes and the effect of radiation to the vertebral bodies on growth trajectories for long-term survivors of high-risk neuroblastoma. *Radiation Oncology*. 2018 Jun; 7(2): 187-193. PubMed PMID: 34178250. PubMed Central PMCID: PMC8225230.
131. Calzada O, Switchenko J, Maly J, Blum K, Grover N, Mathews S, Park S, Gordon M, Danilov A, Flowers C, Cohen J. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. *Leukemia and Lymphoma*. 2018 Dec; 59(12): 2862-2870. PubMed PMID: 29912594. PubMed Central: PMCID: PMC6360945.

132. Koff JL, Li J, Zhang XA, Switchenko JM, Flowers CR, Waller EK. Impact of post-transplant lymphoproliferative disorder subtype on survival. *Cancer*. 2018 Jun 1; 124(11): 2327-2336. PubMed PMID: 29579330; PubMed Central PMCID: PMC5992039.
133. Greenwell I, Staton A, Lee M, Switchenko J, Saxe D, Maly J, Blum K, Grover N, Mathews S, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Park S, Flowers C, Cohen J. Complex karyotype in mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. *Cancer*. 2018 Jun 1; 124(11): 2306-2315. PubMed PMID: 29579328; PubMed Central PMCID: PMC5992038.
134. Zhong J, Switchenko JM, Behera M, Kooby D, Maithel SK, McDonald MW, Lin JY, Cassidy RJ, El-Reyes B, Landry J, Patel PR. Chemotherapy with or without definitive radiation therapy in inoperable pancreatic cancer. *Annals of Surgical Oncology*. 2018 Apr; 25(4): 1026-1033. PubMed PMID: 29327180; PubMed Central PMCID: PMC5951381.
135. Danish H, Ferris M, Balagamwala E, Switchenko JM, Patel K, Chowdhary M, Craven C, Mendoza P, Suh J, Bergstrom C, Grossniklaus H, Aaberg T, Singh A, Crocker I, Khan MK. Comparative outcome and toxicity of ruthenium-106 and palladium-103 in the definitive treatment of choroidal melanoma. *Melanoma Research*. 2018 Apr; 28(2): 120-125. PubMed PMID: 29303890; PubMed Central PMCID: PMC5828969.
136. Chowdhary M, Okwan-Duodo D, Switchenko JM, Press RH, Jhaveri J, Buchwald ZS, Zhong J, Chapman BV, Bindra RS, Contessa JN, Park HS, Yu JB, Decker RH, Olson JJ, Oyesiku NM, Abrams RA, Shu HG, Curran WJ, Crocker IR, Patel KR. The effect of angiotensin receptor blockade on symptomatic radiation necrosis following stereotactic radiosurgery. *Journal of Neuro-oncology*. 2018 Jan; 136(2): 289-298. PubMed PMID: 29124649; PubMed Central PMCID: PMC5784434.
137. Sadigh G, Carlos R, Jiang R, Switchenko JM, Ward K, Applegate K, Duszak R. Downstream Breast Imaging Following Screening Mammography in Medicare Patients with Advanced Cancer: A Population-Based Study. *Journal of General Internal Medicine*. 2018 Mar; 33(3):284-290. PubMed PMID: 29139055; PubMed Central PMCID: PMC5834957.
138. Cassidy RJ, Zhang X, Switchenko JM, Patel PR, Shelton JW, Tian S, Nanda RH, Steuer CE, Pillai RN, Owonikoko TK, Ramalingam SS. Healthcare disparities among octogenarians and nonagenarians with stage III lung cancer. *Cancer*. 2018 Feb 15; 124(4): 775-784. PubMed PMID: 29315497; PubMed Central PMCID: PMC5801133.
139. Jhaveri J, Zhang A, Chowdhary M, Press RH, Switchenko JM, Morgan TM, Roper J, Dhabaan A, Elder E, Olson JJ, Eaton BR, Curran WJ, Shu HG, Crocker IR, Patel KR. Does size matter? Investigating the optimal planning target volume margin for post-operative stereotactic radiosurgery to resected brain metastasis. *Journal of Neurosurgery*. 2018 Jan; 126(1): 100-106. PubMed PMID: 29676690. PubMed Central PMCID: PMC6195865.
140. Ferris MJ, Zhong J, Switchenko JM, Higgins KA, Cassidy RJ, McDonald MW, Eaton BR, Miller AH, Bruner DW, Xiao C, Beitler JJ. Brainstem Dose is Associated with Patient-Reported Acute Fatigue in Head and Neck Cancer Radiation Therapy. *Radiotherapy and Oncology*. 2018 Jan; 126(1): 100-106. PubMed PMID: 28826628. PubMed Central PMCID: PMC5841457.
141. Guidot DM, Switchenko JM, Nastoupil LJ, Koff JL, Blum KA, Maly J, Flowers CR, Cohen JB. Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. *Leukemia and Lymphoma*. 2018 Apr; 59(4):888-895. PubMed PMID: 28797213. PubMed Central PMCID: PMC6374125.
142. Dhere VR, Edelman S, Waller EK, Langston AA, Graiser M, Connelly EC, Switchenko JM, Esiashvili N, Khan M. Myeloablative Busulfan/Cytosine Arabinoside Conditioning vs. Reduced-intensity Fludarabine/Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplant in Patients with Acute Myelogenous Leukemia. *Leukemia and Lymphoma*. 2018 Apr; 59(4): 837-843. PubMed PMID: 28782395. PubMed Central PMCID: PMC5841460.

143. Cassidy RJ, Nour SG, Liu T, Switchenko JM, Tian S, Ferris MJ, Press RH, Zhong J, Abuigideiri M, Rossi PJ, Jani AB. Reproducibility in contouring the neurovascular bundle for prostate cancer radiotherapy treatment planning. *Practical Radiation Oncology*. 2018 May - Jun; 8(3): e125-e131. PubMed PMID: 28939353. PubMed Central PMCID: PMC5942224.
144. Allen SC, Dixon MD, Switchenko JM, Pentz RD. Cancer donor preferences for disposition of their biospecimens after biobank closure. *Cancer*. 2017 Dec 1; 123(23): 4648-4652. PubMed PMID: 28746751; PubMed Central PMCID: PMC5693705.
145. Kendi AT, Brandon D, Switchenko JM, Wadsworth JT, Saba N, Schuster DM. Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) – external validation study. *American Journal of Nuclear Medicine and Molecular Imaging*. 2017 Sep 1; 7(4): 174-180. PubMed PMID: 28913156; PubMed Central PMCID: PMC5596320.
146. Cassidy RJ, Switchenko JM, Cheng E, Jiang R, Jhaveri J, Tanenbaum DG, Russell MC, Steuer CE, Gillespie TW, McDonald MW, Landry JC. Healthcare disparities among octogenarians and nonagenarians with stage II and III rectal cancer. *Cancer*. 2017 Nov 15; 123(22): 4325-4336. PubMed PMID: 28759121; PubMed Central PMCID: PMC5673500.
147. Sadigh G, Holder CA, Switchenko JM, Dehkharghani S, Allen JW. Is there added value in obtaining a cervical spine MRI in the assessment of non-traumatic angiographically-negative subarachnoid hemorrhage? A retrospective study and meta-analysis of the literature. *Journal of Neurosurgery*. 2018 Sep; 129(3): 670-676. PubMed PMID: 29027857; PubMed Central PMCID: PMC5899067.
148. Zhong J, Ferris M, Switchenko JM, Press RH, Buchwald Z, Olson JJ, Eaton BR, Curran WJ, Shu HG, Crocker IR, Patel KR. Post-operative stereotactic radiosurgery for resected brain metastases: A comparison of outcomes for large resection cavities. *Practical Radiation Oncology*. 2017 Nov - Dec; 7(6): e419-e425. PubMed PMID: 28668668. PubMed Central PMCID: PMC5949048.
149. Chowdhary M, Chhabra AM, Switchenko JM, Jhaveri J, Sen N, Patel PR, Curran WJ, Abrams RA, Patel KR, Marwaha G. Domestic job shortage or job maldistribution? A geographic analysis of the current radiation oncology job market. *International Journal of Radiation Oncology\*Biophysics*. 2017 Sep 1; 99(1): 9-15. PubMed PMID: 28816168; PubMed Central PMCID: PMC5656001.
150. Zhong J, Patel KP, Switchenko JM, Gillespie T, Cassidy RJ, Patel P, Kooby D, Landry J. Comparison of outcomes in patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy (SBRT) versus conventionally fractionated radiation. *Cancer*. 2017 Sep 15; 123(18): 3486-93. PubMed PMID: 28493288; PubMed Central PMCID: PMC5589506.
151. Cassidy RJ, Patel PR, Zhang X, Press RH, Switchenko JM, Pillai RP, Owonikoko TK, Ramalingam SS, Fernandez FG, Force SD, Curran WJ, Higgins KA. Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis. *Clinical Lung Cancer*. 2017 Sep; 18(5): 551-558. PubMed PMID: 28373068. PubMed Central PMCID: PMC5783539.
152. Guo X, Koff J, Moffit A, Cinar M, Ramachandiran S, Chen Z, Switchenko J, Mosunjac M, Neil S, Mann K, Bagirov M, Natkunam Y, Khoury H, Rossi M, Harris W, Flowers C, Lossos I, Boise L, Dave S, Kowalski J, Bernal L. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. *Oncogene*. 2017 Jul 20; 36(29): 4224-4232. PubMed PMID: 28368397.
153. Sadigh G, Carlos R, Jiang R, Switchenko JM, Ward K, Applegate K, Duszak R. Breast cancer screening in patients with newly diagnosed lung and colorectal cancer: A population-based study of utilization. *Journal of the American College of Radiology*. 2017 Jul; 14(7): 900-910. PubMed PMID: 28325489. PubMed Central PMCID: PMC5588859.
154. Patel KP, Prabhu RS, Switchenko JM, Craven C, Mendoza P, Danish H, Zhong J, Grossniklaus H, Aaberg T, Aaberg T, Reddy S, Butker E, Bergstrom C, Crocker I. Visual acuity, oncologic, and toxicity outcomes with

- palladium 103 (103Pd) versus iodine 125 (125I) plaque treatment for choroidal melanoma. *Brachytherapy*. 2017 May - Jun; 16(3):646-653. PubMed PMID: 28262517. PubMed Central PMCID: PMC5586039.
155. Sayan M, Cassidy R, Switchenko JM, Kayode O, Saba N, Steuer C, Shin D, Wadsworth JT, El-Deiry M, Patel M, Beitler J, Higgins K. Development of late toxicities in patients with oral tongue cancer treated with surgical resection and adjuvant radiation therapy. *Frontiers in Oncology*. 2017 Jan 11; 6:272. PubMed PMID: 28123995; PubMed Central PMCID: PMC5225102.
  156. Ferris M, Danish H, Switchenko J, Deng C, George BA, Goldsmith KC, Wasilewski KJ, Cash WT, Khan MK, Eaton BR, Esiashvili N. Favorable local control for consolidative radiotherapy without dose escalation in high-risk neuroblastoma despite gross residual disease, positive margins, or nodal involvement. *International Journal of Radiation Oncology\*Biology\*Physics*. 2017 Mar 15; 97(4): 806-812. PubMed PMID: 28244417; PubMed Central PMCID: PMC5502807.
  157. Pinhiero AM, Pocock RH, Switchenko JM, Dixon M, Shaib WL, Ramalingam SS, Pentz RD. Discussing molecular testing in Oncology Care: Comparing patient and physician information preferences. *Cancer*. 2017 May 1; 123(9): 1610-1616. PubMed PMID: 28140456; PubMed Central PMCID: PMC5400669.
  158. White TE, Hendershot KA, Dixon MD, Pelletier W, Haight A, Stegenga K, Alderfer MA, Cox L, Switchenko JM, Hinds P, Pentz RD. Family strategies to support siblings of pediatric hematopoietic stem cell transplant patients. *Pediatrics*. 2017 Feb; 139(2). PubMed PMID: 28119426; PubMed Central PMCID: PMC5260146.
  159. Cassidy RJ, Switchenko JM, Jegadeesh N, Ferris MJ, Eaton BR, Higgins KA, Wadsworth JT, Saba N, Beitler JJ. Association of lymphovascular space invasion with locoregional failure and survival in patients with node-negative oral tongue cancers. *JAMA Otolaryngol Head Neck Surg*. 2017 Apr 1; 143(4): 382-388. PubMed PMID: 28097311; PubMed Central PMCID: PMC5398912.
  160. Danish HH, Patel KR, Switchenko JM, Gillespie TW, Jhaveri J, Chowdhary M, Abugideiri M, Delman KA, Lawson DH, Khan MK. The influence of post-operative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Data Base analysis. *Melanoma Research*. 2016 Dec; 26(6): 595-603. PubMed PMID: 27575390; PubMed Central PMCID: PMC5372697.
  161. Davis CC, Zelnak A, Eley JW, Goldstein DA, Switchenko JM, McKibbin T. Clinical utility of routine cardiac monitoring in breast cancer patients receiving trastuzumab. *Annals of Pharmacotherapy*. 2016 Sep; 50(9): 712-7. PubMed PMID: 27307412; PubMed Central PMCID: PMC4983504.
  162. Sadigh G, Nandwana S, Moreno C, Cox K, Baumgarten D, Switchenko J, Easter T, Applegate K. Assessment of added value of non-contrast to contrast-enhanced abdominal CT scan for characterization of hypervascular liver metastases. *Current Problems in Diagnostic Radiology*. 2016 Nov - Dec; 45(6):373-379. PubMed PMID: 27397022. PubMed Central PMCID: PMC5655799.
  163. Bulka C, Nastoupil L, Koff JL, Bernal L, Ward K, Williams JN, Bayakly AR, Switchenko JM, Waller LA, Flowers CR. Relationships between residential proximity to Environmental Protection Agency designated toxic release sites and diffuse large B-cell lymphoma. *Southern Medical Journal*. 2016 Oct; 109 (10): 606-614. PubMed PMID: 27706495; PubMed Central PMCID: PMC5076563.
  164. Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ, Prabhu RS, Khan MK. BRAF inhibitor and stereotactic radiosurgery is associated with increased risk of radiation necrosis. *Melanoma Research*. 2016 May 24; 26(4): 387-94. PubMed PMID: 27223498; PubMed Central PMCID: PMC4943024.
  165. Lawson J, Switchenko JM, McKibbin T, Harvey RD. Impact of isotope dilution mass spectrometry (IDMS) standardization on carboplatin dose and adverse events. *Pharmacotherapy*. 2016 Jun; 36(6): 617-22. PubMed PMID: 27130286; PubMed Central PMCID: PMC5372694.

166. Kendi TK, Mudalegundi S, Switchenko J, Lee D, Halkar R, Chen AY. Assessment of the role of different imaging modalities with emphasis on Fdg Pet/Ct in the management of well differentiated thyroid cancer (WDTC). *Journal of Thyroid Disorders & Therapy*. 2016, 5:1. PubMed PMID: 28966886; PubMed Central PMCID: PMC5616213.
167. Danish HH, Heumann TR, Bradley KT, Switchenko J, Esiashvili N, Lechowicz MJ, Flowers CR, Khan MK. CD30+ cutaneous T cell lymphoma: Response to rotational total skin electron irradiation. *Dermatology and Therapy*. 2016 Jun; 6(2): 251-63. PubMed PMID: 27085537; PubMed Central PMCID: PMC4906109.
168. Kendi A, Magliocca K, Corey A, Galt J, Switchenko J, Wadsworth J, El-Deiry M, Hudgins P, Schuster D, Saba N. Is there a role for PET/CT parameters to characterize benign, malignant, and metastatic parotid tumors? *American Journal of Roentgenology*. 2016 Sep; 207(3): 635-640. PubMed PMID 27276388. PubMed Central PMCID: PMC4993674.
169. Don H, Dossul T, Bernal L, Switchenko J, Ndibe C, Ibraheem A, Dixon M, Langston A, Nooka A, Flowers C, Pentz R, Waller E. Referral patterns and clinical outcomes for transplant-eligible lymphoma and myeloma patients evaluated at an urban county hospital. *Journal of Stem Cell Research & Therapy*. 2016, 6:2. PubMed PMID: 28966870; PubMed Central PMCID: PMC5616211.
170. Switchenko JM, Bulka C, Ward K, Koff JL, Bayakly AR, Ryan PB, Waller LA, Flowers CR. Resolving uncertainty in the spatial relationship between passive benzene exposure and risk of non-Hodgkin lymphoma. *Cancer Epidemiology*. 2016 Apr; 41: 139-51. PubMed PMID: 26949112; PubMed Central PMCID: PMC4946246.
171. Ganju RG, Nanda RH, Esiashvili N, Switchenko JM, Wasilewski-Masker K, Marchak JG. The effect of transition clinics on knowledge of diagnosis and perception of risk in young adult survivors of childhood cancer. *Journal of Pediatric Hematology and Oncology*. 2016 Apr; 38(3): 197-201. PubMed PMID: 26925717; PubMed Central PMCID: PMC4937789.
172. Camarata AS, Switchenko JM, Demidenko E, Flood AN, Swartz HM, Ali AN. Emesis as a screening diagnostic for low dose rate (LDR) total body radiation exposure. *Health Physics*. 2016 Apr; 110(4): 391-4. PubMed PMID: 26910032; PubMed Central PMCID: PMC4770573.
173. Kowalski J, Dwivedi B, Newman S, Switchenko JM, Pauly R, Gutman DA, Arora J, Gandhi K, Ainslie K, Doho G, Qin S, Moreno CS, Rossi M, Vertino P, Lonial S, Bernal L, Boise LH. Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. *Nucleic Acids Research*. 2016 Apr 20; 44(7): e69. PubMed PMID: 26826710; PubMed Central PMCID: PMC4838358.
174. Oliver DE, Patel KR, Switchenko J, Parker D, Lawson DH, Delman KA, Kudchadkar RR, Khan MK. Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. *Melanoma Research*. 2016 Feb; 26(1): 35-41. Pubmed PMID: 26397051; PubMed Central PMCID: PMC4869869.
175. Cassidy RJ, Jegadeesh N, Switchenko J, Rajpara R, Esiashvili N, Flowers CR, Khan MK. The role of consolidative radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era. *Leukemia and Lymphoma*. 2016 Jan 12; 1-7. PubMed PMID: 26460996; PubMed Central PMCID: PMC4949106.
176. Roper J, Chanyavanich V, Betzel G, Switchenko J, Dhakaan A. Single isocenter multiple-target SRS: Risk of compromised coverage. *International Journal of Radiation Oncology, Biology, Physics*. 2015 Nov 1; 93(3): 540-6. PubMed PMID: 26460996; PubMed Central PMCID: PMC4610743.
177. Kandula S, Switchenko JM, Harari S, Fasola C, Mister D, Yu DS, Zelnak AB, Torres MA. Locoregional recurrence risk in breast cancer patients with estrogen receptor positive tumors and residual nodal disease following neoadjuvant chemotherapy and mastectomy without radiation therapy. *International Journal of Breast Cancer*. 2015; 2015: 147476. PubMed PMID: 26266050; PubMed Central PMCID: PMC4523670.
178. Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously

untreated indolent non-Hodgkin's lymphoma. *British Journal of Haematology*. 2015 Nov; 171(4): 539-46. PubMed PMID: 26248505; PubMed Central PMCID: PMC4626332.

179. Beitler JJ, Mikell JL, Switchenko J. Human papillomavirus-related oropharyngeal cancer: Agree with a new staging system, but the devil is in the details. *Journal of Clinical Oncology*. 2015 Oct 1; 33(28): 3217-8. PubMed PMID: 26215957.
180. Hanasoge S, Magliocca KR, Switchenko JM, Saba NF, Wadsworth JT, El-Deiry MW, Shin DM, Khuri F, Beitler JJ, Higgins KA. Clinical outcomes in elderly patients with human papilloma-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy. *Head & Neck*. 2016 Jun; 38(6): 846-51. PubMed PMID: 2589939; PubMed Central PMCID: PMC4959784.
181. Rudra S, Yu DS, Yu ES, Switchenko JM, Mister D, Torres MA. Locoregional recurrence patterns in young versus elderly women treated for breast cancer. *International Journal of Breast Cancer*. 2015; 2015: 213123. PubMed PMID: 25949828; PubMed Central PMCID: PMC4408642.
182. Kendi AT, Corey A, Magliocca KR, Nickleach DC, Galt J, Switchenko JM, El-Deiry MW, Wadsworth JT, Judgins PA, Saba NF, Schuster DM. 18-F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis better than the numbers? *European Journal of Radiology*. 2015 Jun; 84(6): 1171-6. PubMed PMID: 25816993; PubMed Central PMCID: PMC4927192.
183. Davis CC, Cohen JB, Shah KS, Hutcherson DA, Surati MJ, Valla K, Panjic EH, Handler CE, Switchenko JM, Flowers CR. The efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large b-cell lymphoma. *Clinical Lymphoma, Myeloma, & Leukemia*. 2015 May; 15(5): 270-7. PubMed PMID: 25704479; PubMed Central PMCID: PMC4869871.
184. Heumann TR, Esiashvili N, Parker S, Switchenko JM, DHabbaan A, Goodman M, Lechowicz MJ, Flowers CR, Khan MK. Total skin electron therapy for cutaneous T cell lymphoma using modern dual field rotational technique. *International Journal of Radiation Oncology, Biology, Physics*. 2015 May 1; 92(1): 183-91. PubMed PMID: 25670538; PubMed Central PMCID: PMC4869883.
185. Pentz RD, Hendershot KA, Wall L, White TE, Peterson SK, Thomas CB, McCormick J, Green MJ, Lewis C, Farmer ZL, Hlubocky FJ, Dossul T, Dixon MD, Liu Y, Switchenko JM, Salvador C, Owonikoko TK, Harvey RD, Khuri FR. Development and testing of a tool for physician assessment of patients' preferences for early phase clinical trial participation. *Psycho-Oncology: Clinical Correspondence*. 2015 Jul; 24(7): 835-8. PubMed PMID: 25530552; PubMed Central PMCID: PMC4474780.
186. Jegadeesh NK, Kim S, Prabhu RS, Oprea GM, Yu DS, Godette KG, Zelnak AB, Mister D, Switchenko JM, Torres MA. The 21-gene recurrence score and locoregional recurrence in breast cancer patients. *Annals of Surgical Oncology*. 2015 Apr; 22(4): 1088-94. PubMed PMID: 254726; PubMed PMCID: PMC4869872.
187. Kandula S, Prabhu RS, Nanda R, Switchenko JM, Cash T, Qayed M, Katzenstein H, Esiashvili N. Outcome after radiation therapy to metastatic sites in patients with stage 4 neuroblastoma. *Journal of Pediatric Hematology and Oncology*. 2015 Apr; 37(3): 175-80. PubMed PMID: 25238225; PubMed Central PMCID: PMC4869887.
188. Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. *Cancer Medicine*. 2014 Dec; 3(6): 1579-94. PubMed PMID: 25124282; PubMed Central PMCID: PMC4298385.
189. Ali AN, Switchenko JM, Kim S, Kowalski J, El-Deiry MW, Beitler JJ. A model and nomogram to predict tumor site origin for squamous cell cancer confined to cervical lymph nodes. *Cancer*. 2014 Nov 15; 120(22): 3469-76. PubMed PMID: 25060659; PubMed PMCID: PMC4232899.

190. Mikell JL, Waller EK, Switchenko JM, Rangaraju S, Ali Z, Graiser M, Hall WA, Langston AA, Esiashvili N, Khoury HJ, Khan MK. Similar survival for patients undergoing reduced-intensity total body irradiation (TBI) versus myeloablative TBI as conditioning for allogeneic transplant in acute leukemia. *International Journal of Radiation Oncology, Biology, Physics*. 2014 Jun 1; 89(2): 360-9. PubMed PMID: 24837891.
191. Hall WA, Colbert LE, Nickleach D, Switchenko J, Liu Y, Gillespie T, Lipscomb J, Hardy C, Kooby DA, Prabhu RS, Kauh J, Landry JC. The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. *Journal of Gastrointestinal Oncology*. 2014 Apr; 5(2): 77-85. PubMed PMID: 24772334; PubMed Central PMCID: PMC3999628.
192. Eaton BR, Losken A, Okwan-Duodu D, Schuster DM, Switchenko JM, Mister D, Godetter K, Torres MA. Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammoplasty and radiotherapy. *Annals of Surgical Oncology*. 2014 Jan; 21(1): 93-9. PubMed PMID: 24081796.
193. Marcus DM, Switchenko JM, Prabhu R, O'Regan R, Zelnak A, Fasola C, Mister D, Torres MA. Neoadjuvant hormonal therapy is associated with comparable outcomes to neoadjuvant chemotherapy in post-menopausal women with estrogen receptor-positive breast cancer. *Frontiers in Oncology*. 2013 Dec 27; 3:317. PubMed PMID: 24409418; PubMed Central PMCID: PMC3873517.
194. Colbert LE, Hall WA, Nickleach D, Switchenko J, Kooby DA, Liu Y, Gillespie T, Lipscomb J, Kauh J, Landry JC. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. *Cancer*. 2014 Feb 15; 120(4): 499-506. PubMed PMID: 24390739; PubMed Central PMCID: PMC4380170.
195. Hall WA, Colbert L, Nickleach D, Shelton J, Marcus DM, Switchenko J, Rossi PJ, Godette K, Cooper S, Jani AB. Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate. *Practical Radiation Oncology*. 2013 Oct; 3(4): e157-64. PubMed PMID: 24674413.
196. Bulka C, Nastoupil LJ, McClellan W, Ambinder A, Phillips A, Ward K, Bayakly AR, Switchenko JM, Waller L, Flowers CR. Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. *Cancer*. 2013 Sep 15; 119(18): 3309-17. PubMed PMID: 23896932; PubMed Central PMCID: PMC4151314.
197. Wood WC, Switchenko JM. Patent foramen ovale and cryptogenic stroke. *New England Journal of Medicine*. 2013 Jul 4; 369(1): 88. PubMed PMID: 23822783.
198. Chen SA, Hiley C, Nickleach D, Petsuksiri J, Andic F, Riesterer O, Switchenko JM, Torres MA. Breast reconstruction and post-mastectomy radiation practice. *Radiation Oncology*. 2013 Mar 2; 8:45. PubMed PMID 23452558; PubMed PMCID: PMC3599934.
199. Marcus DM, Marcus RP, Prabhu RS, Owonikoko TK, Lawson DH, Switchenko J, Beitler JJ. Rising incidence of mucosal melanoma of the head and neck in the United States. *Journal of Skin Cancer*. 2012; 2012: 231693. PubMed PMID: 23251803; PubMed PMCID: PMC3518053.
200. Schmotzer B, Kilgo P, Switchenko J. 'The Natural?' The effect of steroids on offensive performance in baseball. *Chance*. 2009; 22(2): 21-32.
201. Schmotzer B, Switchenko JM, Kilgo P. Did steroid use enhance the performance of the Mitchell batters? The effect of alleged performance enhancing drug use on offensive performance from 1995-2007. *Journal of Quantitative Analysis in Sports*. 2008; 4(3): 1-4.

*Book chapters:*

1. Waller LA, Wheeler DC, Switchenko JM. Focused clustering: Statistical analysis of spatial patterns of disease around putative sources of increased risk. *Handbook of Spatial Epidemiology*. 2016.

*Manuscripts Submitted:*

1. Ajay PS, Rajamanickam RK, Rhee K, NeMoyer R, Goyal S, Switchenko JM, Lin Y, Jabbour SK, Carpizo DR, Paulos CM, Kennedy TJ, Shah MM. Identifying the optimal treatment strategy in patients with resectable noncardia gastric cancer. Submitted to Surgical Endoscopy on 6/6/23.
2. Akce M, Farran B, Switchenko JM, Rupji M, Kang S, Khalil L, Ruggieri-Joyce A, Olson B, Shaib WL, Wu C, Alese OB, Lesinski GB, El-Rayes B. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer. Submitted to Journal for ImmunoTherapy of Cancer on 5/18/23.
3. Behera M, Jiang R, Huang Z, Bunn B, Wynes MW, Switchenko JM, Scagliotti G, Belani CP, Ramalingam SS. Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR exon 20 insertion mutation: An IASLC-ASCO CancerLinQ study. Submitted to Journal of Thoracic Oncology on 5/8/23.
4. Ajay PS, Sok C, Switchenko JM, Maegawa FB, Gillespie TW, Paulos CM, Kooby DA, Kennedy TJ, Shah MM. Adjuvant therapy determines the fate of clinically node negative resected gastric cancer patients upstaged to pathologically node positive disease. Submitted to European Journal of Surgical Oncology on 5/5/23.
5. Janopaul-Naylor JR, Switchenko JM, Corriher TJ, Filson CP, Esdaille A, Hanasoge S, Mahal B, Patel S. Disparities in prostate cancer treatment initiation before and after the Affordable Care Act. Submitted to Cancer Medicine on 4/20/23.
6. Robinson MH, Villa N, Jaye D, Nooka A, Duffy A, McCachren S, Manalo J, Switchenko JM, Barnes S, Horvat A, Parihar V, Gong J, Liang Y, Smith G, Gupta V, Boise L, Kaufman J, Hofmeister C, Joseph NS, Lonial S, Dhodapkar K, DHodapkar M. Regulation of antigen-specific T-cell infiltration and spatial tumor-immune architecture in myeloma and premalignancy. Submitted to Journal of Clinical Investigation on 4/23/23.
7. Seong CS, Huang C, Boese AC, Hou Y, Koo J, Mouw AK, Johns MA, Rupji M, Joseph G, Johnston HR, Claussen H, Switchenko JM, Behera M, Churchman M, Marcus AI, Zhou W, Ramalingam S, Fu H, Gilbert-Ross M. Loss of the endocytic tumor suppressor HD-PTP is mutually exclusive with mutations in LKB1 and promotes Ras-driven tumor oncogenesis. Submitted to Cell Reports on 4/27/23.
8. Akce M, Farran B, Switchenko JM, Rupji M, Kang S, Khalil L, Ruggieri-Joyce A, Olson B, Shaib WL, Wu C, Alese OB, Diab M, Lesinski GB, El-Rayes B. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer. Submitted to Journal for ImmunoTherapy of Cancer on 4/12/23.
9. Casabianca AS, Ajay PS, Rajamanickam RK, Rhee K, Goyal S, Switchenko JM, Lin Y, Jabbour SK, August DA, Alexander HR, Carpizo DR, Kennedy TJ, Shah MM, NeMoyer R. Identifying the optimal adjuvant or neoadjuvant treatment strategy in patients undergoing curative intent gastric cancer resection. Submitted to Journal of Gastrointestinal Surgery on 4/2/23.
10. Daddacha W, Schlafstein AJ, Withers AE, Thompson EB, Danelia D, Mahboubi B, Yang X, Buchwald ZS, Dynan WS, Switchenko JM, Kim B, Khan MK, Jaye DL, Yu D. SAMHD1 expression governs doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients. Submitted to NAR Cancer on 3/23/23.
11. Lalonde CS, Switchenko JM, Behera M, Bilen MA, Owonikoko TK, Lewis CM, Hitron E, Collins H, Judson EC, Alese OB, Cavalcante L, Harvey RD, Carlisle JW. Shifting sociodemographic characteristics of a phase I clinical trial population at an NCI-designated Comprehensive Cancer Center in the Southeast. Submitted to the Oncologist on 2/27/23.
12. Koff JL, Karadkhele GM, Switchenko JM, Rupji M, Little K, Larsen C. Post-transplant lymphoproliferative disorder risk and outcomes in renal transplant patients treated with belatacept immunosuppression. Submitted to Clinical Transplantation on 2/7/23.



13. Rowling BC, Tiao E, Casem K, Davis C, Draper A, Switchenko JM, El-Rayes B, Alese O. Safety and efficacy of nanoliosomal irinotecan plus fluorouracil without leucovorin in previously treated metastatic pancreatic adenocarcinoma. Submitted to *Pancreas* on 12/16/22.
14. Kleber T, Switchenko JM, Lawson D, Buchwald Z, Khan MK. Real world outcomes of melanoma brain metastases treated with immunotherapy with or without stereotactic radiosurgery. Submitted to *Melanoma Research* on 10/12/22.
15. Shu Z, Dwivedi B, Switchenko JM, Yu D, Ramalingam S, Deng X. PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer. Submitted to *Nature Communications* on 8/31/22.
16. Wu R, Gogineni K, Meisel J, Szabo S, Thirunavu M, Friend S, Bercu Z, Sethi I, Natarjan N, Switchenko JM, Levy J, Abdalla E, Weakland L, Zelnak A, Volas-Redd G, Bowen K, Kalinsky K, Kokabi N. Study protocol: Efficacy and safety of radioembolization (REM\_ as an early modality (EM) therapy for metastatic breast cancer (BR) to the liver with Y90 (REMEMBER Y90). Submitted to *CardioVascular and Interventional Radiology* on 7/13/22.
17. Casabianca AS, Rajamanickam RK, Rhee K, NeMoyer R, Goyal S, Switchenko JM, Lin Y, Jabbour SK, August DA, Alexander HR, Carpizo DR, Kennedy TJ Shah MM. Identifying the optimal adjuvant or neoadjuvant treatment strategy in patients undergoing curative intent gastric cancer resection. Submitted to *European Journal of Surgical Oncology* on 6/25/22.
18. Ajay PS, NeMoyer R, Goyal S, Switchenko JM, Lin Y, Jabbour SK, Carpizo DR, Paulos CM, Kennedy TJ. Does resectable gastric cancer of the cardia warrant a different treatment strategy? Submitted to *European Journal of Surgical Oncology* on 6/16/22.
19. Aldrich J, Ekpo P, Rupji M, Switchenko JM, Torres MA, Kalinsky K, Bhawe MA. Minority enrollment and clinical outcomes in breast cancer clinical trials at an urban medical center: A retrospective review. Submitted to *Clinical Breast Cancer* on 5/5/22.
20. Casabianca AS, Tsagkalidis V, Burchard PM, Chacon A, Melucci AD, Reitz A, Swift DA, McCook AA, Switchenko JM, Carpizo DR, Shah MM. Surgery in combination with systemic chemotherapy is associated with improved survival in stage IV gallbladder cancer. Submitted to *European Journal of Surgical Oncology* on 5/4/22.
21. Robinson MH, Villa N, Jaye DL, Nooka AK, Duffy A, McCachren SS, Manalo J, Horvat A, Parihar VC, Smith GH, Switchenko JM, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Dhodapkar KM, Dhodapkar MV. Regulation of T-cell infiltration and spatial tumor-immune architecture in myeloma and premalignancy. Submitted to *Blood Cancer Discovery* on 3/15/22.
22. Shah MM, Casabianca A, Rajamanickam RK, Rhee K, NeMoyer R, Goyal S, Switchenko JM, Lin Y, Jabbour SK, August DA, Alexander HR, Carpizo DR, Kennedy TJ. Identifying the optimal adjuvant or neoadjuvant treatment strategy in patients undergoing curative intent gastric cancer resection. Submitted to *Annals of Surgical Oncology* on 3/7/22.
23. Casabianca AS, Tsagkalidis V, Burchard P, Ullman NA, Chacon A, Melucci A, Reitz A, Swift D, McCook A, Switchenko JM, Shah MM, Carpizo D. Surgery in Combination with Systemic Chemotherapy is Associated with Improved Survival in Stage IV Gallbladder Cancer. Submitted to *Annals of Surgical Oncology* on 1/21/22.
24. Tian S, Switchenko JM, Sethi I, Yang X, Da Silva AJ, Shirvani SM, Owonikoko TK, Schuster DM, Curran WJ, Higgins KA. Characterization of inter-fraction 18-FDG PET variability during lung SBRT: Results of a prospective pilot study. Submitted to *Advances in Radiation Oncology* on 1/11/22.
25. Martini DJ, Goyal S, Switchenko JM, Lechowicz MJ, Allen PB. African American and Caucasian patients with Sézary Syndrome have no differences in outcomes at an ethnically diverse urban medical center. Submitted to *Leukemia and Lymphoma* on 11/7/21.

26. Hess CB, Eng T, Dhere V, Kleber T, Nasti TH, Switchenko JM, Weinberg BD, Rouphael N, Ahmed R, Khan MK. Reproducibility of reduced intubation following whole-lung low-dose radiation therapy (LD-RT) in patients with COVID-19-related pneumonia and oxygen dependence. Submitted to Cancer on 4/26/21.
27. Alese OB, Zhang C, Zakka K, Kim S, Wu C, Shaib WL, Akce M, Chen Z, Switchenko JM, El-Rayes BF. In-hospital pain management among US cancer patients: a cost analysis of the National Inpatient Sample database. Submitted to Current Oncology on 3/2/21.
28. Hess CB, Eng T, Dhere V, Kleber T, Nasti TH, Switchenko JM, Weinberg BD, Rouphael N, Ahmed R, Khan MK. Low-dose whole-lung radiation with dexamethasone and/or remdesivir for patients with COVID-19-related acute respiratory distress syndrome (ARDS). Submitted to Cancer on 2/10/21.
29. Tian S, Switchenko JM, Sethi I, Yang X, Da Silva AJ, Shirvani SM, Owonikoko TK, Schuster DM, Curran WJ, Higgins KA. Characterization of inter-fraction 18-FDG PET variability during lung SBRT: Results of a prospective pilot study. Submitted to International Journal of Radiation Oncology, Biology & Physics on 1/19/21.
30. Switchenko JM, Jennings J, Waller LA. On spatial modeling of the basic reproduction number in hierarchical models of epidemic dynamics. Submitted to Spatial Statistics on 1/24/20.
31. Shaib WL, Zakka K, Li Y, Ghosn N, Skeif A, Switchenko JM, Alese OB, Wu C, Akce M, El-Rayes BF. Chemoradiation compared to radiation therapy alone for T1N0 anal squamous cell carcinoma. Submitted to The Oncologist on 1/22/20.
32. Schlafstein AJ, Abidi SA, Switchenko JM, Buchwald Z, Kirmani K, Flowers CR, Esiashvili N, Khan MK. Consolidative radiotherapy for bulky stage I/II diffuse large B-cell lymphoma (DLBCL) improves local control and progression-free survival, with trends in improving overall survival: A single institution retrospective analysis. Submitted to Leukemia & Lymphoma on 8/12/19.
33. Allen PB, Switchenko JM, Khan MK, Parker S, Flowers CR, Lechowicz MJ. Sequence of therapy in advanced stage cutaneous T-cell lymphoma. Submitted to Leukemia & Lymphoma on 7/15/19.
34. Haybin M, Lohani M, Switchenko JM, Dixon MD, Pentz RD. Improving Patient Understanding of Key Terms Used to Describe Chemotherapy with Animated Videos. Submitted to Cancer on 10/2/18.
35. Madden N, Danish H, Cassidy RJ, Abugideiri M, Switchenko JM, Rai A, Flowers CR, Esiashvili N, Jegadeesh N, Khan MK. Patients over 65 treated with consolidative radiation for early stage diffuse large B cell lymphoma experienced decreased hematologic toxicity and few hospitalizations than RCHOP alone. Submitted to Leukemia and Lymphoma on 5/9/18.
36. Ferris MJ, Switchenko JM, Xiao C, McDonald MW, Eaton BR, Higgins KA, Press RH, Tian S, Steuer CE, Baddour HM, Miller AH, Bruner DW, Beitler JJ. Medulla dose is positively associated with sensation of thirst and midbrain dose is inversely associated with pain: Prospectively collected patient-reported toxicities and brainstem dose in head and neck cancer radiation therapy. Submitted to Red Journal on 3/12/18.
37. Shah RP, Pinheiro AP, Switchenko J, Dixon M, Owonikoko TK, Szabo SM, Pentz RD. Physician communication and patient understanding of molecular testing of tumors. Submitted to Cancer on 1/23/18.
38. Ramachandiran S, Koff JL, Munevver C, Garderet L, Abdel-Wahab O, Matulis SM, Ikhlef S, Dwivedi B, El-Cheikh J, Switchenko JM, Saxe D, Rossi MR, Young AN, McLemore M, Du Y, Sunay S, Khoury HJ, Kaufman JL, Levine RL, Boise LH, Kowalski J, Lonial S, Bernal-Mizrachi L. Loss of NFKB2 3'-end reduces bortezomib response in multiple myeloma. Submitted to Nature Communications on 9/18/17.
39. Colbert L, Dharmarajan K, Switchenko J, Taniguchi CM, Hall WA, Gillespie TW, Kooby DA, Lipscomb J, Landry JC. Radiation for pancreatic adenocarcinoma: an end of life treatment? Radiation therapy for pancreatic adenocarcinoma in the National Cancer Data Base. Submitted to Cancer Medicine on 8/9/17.

40. Danish H, Ferris M, Balagamwala E, Switchenko JM, Patel K, Chowdhary M, Craven C, Mendoza P, Suh J, Bergstrom C, Grossniklaus H, Aaberg T, Singh A, Crocker I, Khan MK. Comparative outcome and toxicity of ruthenium-106 and palladium-103 in the definitive treatment of choroidal melanoma. Submitted to Melanoma Research on 4/21/17.
41. Saba N, Rossi M, Dwivedi B, Switchenko JM, Magliocca K, Zhang H, Patel M, El-Deiry M, Wadsworth T, Chen GZ, Kowalski J, Shin DM. Gene expression signatures in pre-malignant lesions of the head and neck as response markers to EGFR and COX-2 inhibitors – a proof of principle analysis. Submitted to European Archives on 4/6/17.
42. Edelman S, Waller EK, Graiser M, Langston AA, Dhere V, Mikell JL, Switchenko JM, Esiashvili N, Khan MK. Total body irradiation-based conditioning vs. chemotherapy-based conditioning for allogeneic hematopoietic stem cell transplant for acute leukemia. Submitted to Leukemia & Lymphoma on 3/19/17.
43. Danish H, Cassidy R, Switchenko J, Flowers C, Esiashvili N, Jegadeesh N, Khan M. Consolidative radiation for early stage diffuse large B cell lymphoma after CHOP or RCHOP for elderly patients: A Surveillance, Epidemiology, and End Results (SEER) database analysis. Submitted to Radiation Oncology on 2/21/17.
44. Liu S, Bulka C, Koff JL, Ward K, Bayakly AR, Waller LA, Flowers CR, Switchenko JM. Spatial epidemiology of chronic lymphocytic leukemia and small lymphocytic lymphoma in the state of Georgia. Submitted to Clinical Leukemia, Lymphoma, and Myeloma on 7/19/16.

---

#### CONFERENCE PRESENTATIONS:

1. Behera M, Switchenko JM, Ramalingam S, Nadaf S. “Lung Cancer Information System: Enabling precision oncology through informatics,” 2023 Annual Lung Cancer SPORE Workshop, June 12-13, 2023, Boston, MA.
2. Marvil C, Sundar P, Orr J, Patel V, Keilin S, Willingham FF, Switchenko JM, Chawla S. “Surgery vs. conservative management in all pancreatic neuroendocrine tumors <2cm in US: An NCDB analysis,” Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023, Chicago, IL.
3. Burchard P, Dave Y, Prael O, Ajay P, Sok C, Goyal S, Switchenko JM, Kooby DA, Carpizo D, Shah MM, Melucci A. “Preoperative therapy confers survival advantage in early-stage pancreatic cancer,” Americas Hepato-Pancreato-Biliary Association (AHPBA) Annual Meeting, March 9-12, 2023, Miami, FL.
4. Schoettler M, French K, Harris A, Bryson E, Watkins B, Qayed M, Switchenko JM, Williams KM. Prospective Study of Allogeneic Pediatric Transplant Associated Thrombotic Microangiopathy- Novel Prognostic Markers, Biologic Interaction and Outcomes,” Tandem Meetings Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, February 15-19, 2023, Orlando FL.
5. Ajay PS, Sok C, Goyal S, Switchenko JM, Maegawa FB, Gillespie TW, Paulos CM, Kooby DA, Kennedy TJ, Shah MM. “Impact of clinical nodal status in choice of therapy in resectable non-cardia gastric cancer,” Academic Surgical Congress Annual Meeting, February 7-9, 2023, Houston, TX.
6. Lowe M, Yushak M, Mokhtari A, Olson B, Switchenko JM, Harutyunyun A, Evans E, Fisher T, Delman K, Parker D, Lesinski G, Kudchadkar R. “Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable stage III melanoma,” European Society for Medical Oncology (ESMO) Annual Meeting, September 9-13, 2022, Paris, France.
7. Schuster DM, Adediran O, Muzahir S, Friend S, Bhave M, Meisel J, Torres MA, Styblo TM, Graham C, Holbrook A, Kalinsky K, Switchenko JM, Fielder B, Crowe R, Ulaner G. “<sup>18</sup>F-Fluciclovine and <sup>68</sup>Ga-PSMA-11 PET/CT for Detection of invasive lobular breast cancer: Interim report from an exploratory trial,” Society of Nuclear Medicine & Molecular Imaging Annual Meeting, June 11-14, 2022, Vancouver, British Columbia, Canada.

8. Huels A, Liu Y, Christenson G, Li Z, Pearce JL, Bayakly R, Lash TL, Ward K, Switchenko JM. “Environmental and social risk factors in association with spatial clustering of childhood cancer incidence,” International Society for Environmental Epidemiology (ISEE) Annual Conference, August 23-26, 2021, New York, NY.
9. Reitz A, Switchenko JM, Gillespie TW. “Medicaid expansion associated with improved nonmetastatic colon cancer survival among patients in the National Cancer Database,” Southeastern Surgical Congress Annual Meeting, August 21-24, 2021, Atlanta, GA.
10. Dhere VR, Tian S, Buchwald Z, Switchenko JM, Ghavidel BB, Fischer-Valuck BW, Patel SA, Patel PR, Jani AB, Bennet JK, Godette KD. “Low dose-rate brachytherapy before or after transurethral resection of the prostate,” American Brachytherapy Society (ABS) Annual Meeting, June 22-25, 2021, Virtual Meeting.
11. Hess CB, Buchwald Z, Stokes WA, Nasti T, Switchenko JM, Weinberg B, Roupheal N, Steinberg JP, Godette K, Murphy DJ, Ahmed R, Curran WJ, Khan MK. “Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia,” American Society for Radiation Oncology (ASTRO) Annual Meeting, October 24-28, 2020, Virtual Meeting.
12. Tian S, Switchenko JM, Yang X, Sethi I, Da Silva AJ, Owonikoko TK, Schuster DM, Curran WJ, Higgins KA. Increased 18-FDG metabolic activity during lung SBRT predicts risk of disease progression: Results from a prospective study of serial inter-fraction PET/CTs,” American Society for Radiation Oncology (ASTRO) Annual Meeting, October 24-28, 2020, Virtual Meeting.
13. Collin LJ, Gaglioni A, Beyer K, Zhou Y, Moore MA, Nash RN, Switchenko JM, Miller-Kleinhenz JM, Ward KC, McCullough LE. “Financial toxicity is associated with increased breast cancer mortality: the role of structural racism on disparities in outcomes,” Society for Epidemiologic Research conference, June 16-19, 2020, Boston, MA.
14. Turgeon MK, Gamboa AC, Rupji M, Lee RM, Switchenko JM, Russell MC, Cardona K, Kooby DA, Staley CA, Maithel SK, Shah MM. “Should signet-ring cell histology alter the treatment approach for gastric cancer? A National Cancer Database study,” Society of Surgical Oncology Annual Cancer Symposium, March 25-28, 2020, Boston, MA.
15. Gamboa AC, Rupji M, Switchenko JM, Lee RM, Turgeon MK, Meyer BI, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. “Time from diagnosis to treatment of pancreatic cancer: An emergency of the mind,” Americas Hepato-Pancreato-Biliary Association (AHPBA) Annual Meeting, March 5-8, 2020, Miami, FL.
16. Bond DA, Switchenko JM, Maddocks K, Churnetski M, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Blum KA, Cohen JB. “Outcomes following early relapse in patients with mantle cell lymphoma,” American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL.
17. Sadigh G, Lava N, Switchenko JM, Duszak R, Krupinski E, Meltzer C, Hugher D, Carlos R. “Patient-reported financial toxicity in multiple sclerosis: Predictors and association with neuroimaging and medication non-adherence,” Radiological Society of North America (RSNA) Annual Meeting, December 1-6, 2019, Chicago, IL.
18. Syed Y, Jiang C, Switchenko JM, Kirmani K, Kelsey C, Khan MK. “Bi-institutional analysis of stage III/IV diffuse large B-cell lymphomas (DLBCL) patients undergoing consolidative radiotherapy: Potential for improved overall survival (OS) and progression-free survival (PFS),” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 15-18, 2019, Chicago, IL.
19. Lee R, Switchenko JM, Ho TB, Arciero CA, Bhawe MA, Subhedar PD. Is routine Oncotype testing in patients over 70 years of age warranted? “An evaluation of the National Cancer Data Base after TAILORx,” American Society of Breast Surgeons (ASBrS) Annual Meeting, April 30-May 5, 2019, Dallas, TX.

20. Chowdhary M, Switchenko JM, Dhawan R, King K, Sen N, Bonomi PD, Batus M, Fidler MJ, Tian S, Marwaha G, Khan MK. "The impact of neutrophil to lymphocyte ratio on survival in patients with early stage lung cancer treated with SBRT," European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting, April 26-30, 2019, Milan, Italy.
21. Churnetski MC, Switchenko JM, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond D, Bader T, Blum KA, Guo J, Martin P, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers C, Cohen JB. "Early post-transplant progression is associated with inferior overall survival in patients with mantle cell lymphoma completing autologous stem cell transplantation in first remission," 2019 BMT Tandem Meetings, February 20-24, 2019, Houston, TX.
22. Abugideiri M, Switchenko J, Tian S, Madden N, Press B, Buchwald ZS, Zhong J, Jhaveri J, Ferris M, Behera M, Monson D, Lin JY, Landry JC, Godette KD, Patel P. "Impact of lymph node dissection and surgical margins on survival outcomes for definitive local surgery in the setting of stage IV soft tissue sarcoma of the extremity at presentation: An NCDB analysis," Radiological Society of North America (RSNA) Annual Meeting, November 25-30, 2018, Chicago, IL.
23. Chowdhary M, Switchenko JM, Sen N, Katz L, Barry PN, Curran W, Wilson LD, Abrams RA, Marwaha G, Patel KR. "Disparities among domestic radiation oncology graduates' job application patterns and top choice preferences," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 21-24, 2018, San Antonio, TX.
24. Ferris MJ, Sykes K, Kayode OA, Wolf J, Press RH, Switchenko JM, Curran WJ, Higgins KA. "Photon-based cardiac sparing via volumetric modulated arc therapy in thoracic radiation therapy for locally advanced non-small cell lung cancer," International Association for the Study of Lung Cancer (IASLC) 19<sup>th</sup> World Conference on Lung Cancer, September 23-26, 2018, Toronto, Canada.
25. Tian S, Switchenko JM, Jhaveri J, Cassidy RJ, Ferris MJ, Press RH, Pfister NT, Patel MR, Saba NF, McDonald MW, Higgins KA, Yu DS, Curran WJ, Gillespie TW, Beitler JJ. "Survival outcomes by HPV status in non-oropharyngeal head and neck cancers: A propensity score matched analysis of population level data," American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018, Chicago, IL.
26. Chowdhary M, Switchenko JM, Abrams RA, Wang D, Gaurav M, Blumenfeld P, Press RH, Jhaveri J, Olson J, Shu HG, Curran WJ, Patel KR. "Neutrophil-to-lymphocyte ratio as a predictor of overall survival in brain metastases following SRS," European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting, April 20-24, 2018, Barcelona, Spain.
27. Cassidy RJ, Switchenko JM, El-Deiry MW, Belcher RH, Zhong J, Steuer CE, Saba NF, McDonald MW, Yu D, Gillespie TW, Beitler JJ. "Postoperative therapy for salivary gland adenoid cystic carcinomas," 2018 Multidisciplinary Head & Neck Cancers Symposium, February 15-17, 2018, Scottsdale, AZ.
28. Switchenko JM, Ryan PB, Waller LA, Flowers CR. "Geospatial exposure to benzene and lymphoma risk in Georgia," Integrative Clinical & Molecular Epidemiology of Hematologic Malignancy Scientific Workshop, American Society of Hematology (ASH) Annual Meeting, December 9-12, 2017, Atlanta, GA.
29. Goldstein JS, Switchenko JM, Behera M, Flowers CR, Koff JL. "Insurance status impacts overall survival in Burkitt lymphoma," American Society of Hematology (ASH) Annual Meeting, December 9-12, 2017, Atlanta, GA.
30. Sadigh G, Ward K, Carlos RC, Jiang R, Switchenko JM, Applegate K, Duszak R. "Surveillance imaging for lung and colorectal cancer after curative intent surgery: A population-based study," Radiological Society of North America (RSNA) Annual Meeting, November 26 – December 1, 2017, Chicago, IL.
31. Sethi I, Fonzi V, Switchenko J, Galt JR, Schuster DM, Kendi AT. "To Study Whether PET/CT Primary and Nodal Parameters are Associated with Event Free Survival in HPV+ Oropharyngeal Carcinoma Patients," Radiological Society of North America (RSNA) Annual Meeting, November 26 – December 1, 2017, Chicago, IL.

32. Cassidy RJ, Nour SG, Liu T, Switchenko JM, Zhong J, Tian S, Ferris MJ, Press RH, Abugideiri M, Rossi PJ, Jani AB. "Reproducibility in contouring the neurovascular bundle for prostate cancer radiotherapy treatment planning," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 24-27, 2017, San Diego, CA.
33. Sadigh G, Applegate KE, Jiang R, Switchenko JM, Ward K, Carlos R, Duszak R. "Screening mammography and downstream diagnostic breast imaging in patients with advanced cancer: A population-based study," Association of University Radiologists Annual Meeting, May 8-11, 2017, Hollywood, FL.
34. Lim J, Switchenko J, Manapragada P, Galt J, NookaA, Kendi A. "Role of PET parameters in multiple myeloma response assessment," Radiological Society of North America (RSNA) Annual Meeting, November 27 – December 2, 2016, Chicago, IL.
35. Russell M, Chawla S, Switchenko J, Gillespie T. "Ethnic, Racial and Socioeconomic Factors in the Receipt of Multimodality Therapy in Gastric Adenocarcinoma, A Study from the National Cancer Data Base (NCDB)," American College of Surgeons Clinical Congress 2016, October 16-20, 2016, Washington, DC.
36. Zhong J, Switchenko J, Jegadeesh N, Gillespie T, Master V, Nieh P, Alemozaffar M, Kucuk O, Carthon B, Filson C, Jani A. "Comparison of outcomes in patients with muscle invasive bladder cancer treated with radical cystectomy versus bladder-preserving chemo-radiation," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
37. Chowdhary M, Patel K, Switchenko J, Kudchadkar R, Lawson D, Danish H, Prabhu R, Khan M. "Increased Risk of Radiation Necrosis following BRAF inhibitor therapy and Stereotactic Radiosurgery," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
38. Danish H, Patel K, Switchenko J, Gillespie T, Jhaveri J, Chowdhuray M, Abugideiri M, Delman K, Lawson D, Khan M. "The Impact of Post-Operative Lymph Node Radiation Therapy on Overall Survival in Stage III Melanoma, a National Cancer Data Base Analysis," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
39. Switchenko J, Waller L, Flowers C. "Exploring exposure assessment using EPA toxic release sites in Georgia," Joint Statistical Meetings (JSM), August 8-13, 2015, Seattle, WA.
40. Switchenko J, Kowalski J. "A generalized filter statistic for integrated, whole-genome analyses of multiple platforms to characterize several groups of similar phenotype," Joint Statistical Meetings (JSM), August 2-7, 2014, Boston, MA.
41. Roper J, Chanyavanich V, Batzel G, Switchenko J, Dhabaan A. "Single-isocenter multiple-target SRS: Risk of compromised coverage," American Association of Physicists in Medicine (AAPM) Annual Meeting, July 20-24, 2014, Austin, TX.
42. Kilgo P, Switchenko J, Superak H, Weiss P, Elon L, Schmotzer B, Waller L. "Are Umpires Really Harder on Rookies? Historical Background and Statistical Results", Society for American Baseball Research (SABR) Meeting, July 6-10, 2011, Long Beach, CA.
43. Switchenko J, Waller L. "Estimating Epidemic Parameters of STI Transmission: A Bayesian Approach Using MCMC Techniques", Joint Statistical Meetings (JSM), July 29-August 5, 2010, Vancouver BC, Canada.
44. Switchenko J, Schmotzer B, Kilgo P, Weiss P, Elon L. "Do Players Make Batting Slumps Worse by Trying to Escape Them?", Society for American Baseball Research (SABR) Meeting, August 4-8, 2010, Atlanta, GA.
45. Switchenko J, Waller L. "Assessing the Spatial Variability of Syphilis in Baltimore in the 1990s using Geographically Weighted Regression Techniques", International Biometric Society for Eastern North American Region (ENAR) Meeting, March 21-24, 2010, New Orleans, LA.

46. Kilgo P, Switchenko J, Schmotzer B, Elon L, Weiss P. “Strategy, Fatigue, or Something Else? Examining the Effect of Defensive Position on Offensive Performance as a Game Progresses”, Society for American Baseball Research (SABR) Meeting, July 29-August 2, 2009, Washington, DC.
47. Switchenko J, Kilgo P, Schmotzer B. “Did Steroid Use Enhance the Performance of the Mitchell 89? The Effect of Performance-Enhancing Drugs on Offensive Performance from 1995–2007”, Society for American Baseball Research (SABR) Meeting, June 26-29, 2008, Cleveland, OH.

## POSTER PRESENTATIONS:

1. Niyogusaba T, Switchenko JM, Rozati S, Iyer SW, Talluru S, Huen A, Greenwell IB, Scribner J, Rangarajan S, Mehta A, Beaven A, Bhatti S, Krishanasamy S, Porcu P, Sethi T, Foss FM, Paulino D, Case K, Lechowicz MJ, Allen PB. “Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis,” American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023, Chicago, IL.
2. Khan MK, Nasti T, Kleber T, Qian J, Switchenko JM, Hess CB, Kaufman JL, Nooka AK, Dhodapkar MV, Obiekwe D, Lonial S, Ahmed R. “Final results of pilot trial to evaluate anti-PD1 and 8 Gy in 1 fx for relapsed refractory multiple myeloma,” American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023, Chicago, IL.
3. Marvil C, Sundar P, Orr J, Patel V, Keilin S, Willingham FF, Switchenko JM, Chawla S. “Survival outcomes and predictors of survival outcomes in pancreatic neuroendocrine tumors in US: An NCDB analysis,” Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023, Chicago, IL.
4. Marvil C, Sundar P, Orr J, Patel V, Keilin S, Willingham FF, Switchenko JM, Chawla S. “Characteristics and survival outcomes of pancreatic neuroendocrine tumors (PNETS) in young patients (< 50 yrs),” Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023, Chicago, IL.
5. Qayed M, Pavletic S, Holtzman N, Hakim F, Switchenko JM, Rose J, Gress R, Flomerfelt F, Justus D, Suffredini A, Farthing D, Rosenberg A, Kleiner D, Halter J, Tamm M, Prince SS, Bubendorf L, Williams K. “Bronchioalveolar lavage and blood biomarkers support TH2 upregulation in BOS after HCT,” EBMT Annual Meeting, Paris, France, April 23-26, 2023.
6. Ajay PS, Sok C, Goyal S, Switchenko JM, Maegawa FB, Gillespie TW, Paulos CM, Kooby DA, Kennedy TJ, Shah MM. “Optimal adjuvant treatment strategy in resectable gastric cancer patients pathologically upstaged to lymph node positive disease,” Gastrointestinal Cancers Symposium (GI ASCO), January 19-21, 2022, San Francisco, CA.
7. Greenwell IB, Switchenko JM, Maddocks KJ, Kahl BS, Craig AF, Alizadeh AA, Allen PB, Marbury AL, Escobar A, Valla K, Williams M, Parikh P, Roberts D, Neely JJ, Palmer A, Blum KA, Cohen JB. “Bendamustine, obinutuzumab and venetoclax results in high complete response rates in untreated mantle cell lymphoma,” American Society of Hematology (ASH) Annual Meeting, December 10-13, 2022, New Orleans, LA.
8. Zhuang TZ, McCook-Veal A, Switchenko JM, Niyogusaba T, Tarabardkar E, Baird K, O’Leary C, Paulino D, Lechowicz MJ, Allen PB. “Characterizing outcomes in visceral cutaneous T-cell lymphoma: A real-world retrospective study,” American Society of Hematology (ASH) Annual Meeting, December 10-13, 2022, New Orleans, LA.
9. Bond DA, Romancik J, Switchenko JM, Berkowitz B, Day J, Farooq U, Ayyappan S, Baird K, Churchman M, Evens A, Pinilla J, Portell C, Maddocks K, Link B, Cohen J, Stephens DM. “Favorable overall survival following first and second relapse of MCL with availability of novel therapies: Results from the LION prospective observational registry,” American Society of Hematology (ASH) Annual Meeting, December 10-13, 2022, New Orleans, LA.

10. Kleber T, Switchenko JM, Lawson D, Buchwald ZS, Khan MK. “Real world outcomes of melanoma brain metastases treated with immunotherapy with or without stereotactic radiosurgery,” American Society for Radiation Oncology (ASTRO) Annual Meeting, October 23-26, 2022, San Antonio, TX.
11. McClary T, Blee S, Avinger A, Dixon MD, Dai Q, Switchenko JM, Pentz RD. “Accounting for the high enrollment of African Americans in Winship Cancer Institute’s myeloma clinical trials,” American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022, Chicago, IL.
12. Behera M, Joseph G, Rupji M, Huang Z, Bunn B, Wynes M, Switchenko JM, Scagliotti S, Higgins KA, Tsao MS, Belani CP, Sequist L, Ramalingam SS. “Long term survival outcomes in NSCLC patients with targeted therapy and immunotherapy: An IASLC analysis of ASCO CancerLinQ Discovery data,” IASLC 2022 World Conference on Lung Cancer, August 6-9, 2022, Vienna, Austria.
13. Abiodun Ojo O, Shaib W, Fourzali Y, Switchenko JM, Rupji M, Muzahir S. “Report of 177Lu-DOTATATE therapy in patients with well differentiated metastatic neuroendocrine tumors: A single center experience,” Society of Nuclear Medicine & Molecular Imaging Annual Meeting, June 11-14, 2022, Vancouver, British Columbia, Canada.
14. Maithel SK, Javle MM, Mahipal SP, Lin BS, Akce M, Switchenko JM, Rupji M, Cao HT, Cleary SP, Rocha FG. “NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitxel for resectable high-risk intrahepatic cholangiocarcinoma,” American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022, Chicago, IL.
15. Farran B, Switchenko JM, Khalil L, Shaib WL, Olson B, Ruggieri A, Wu C, Alese OB, Diab M, Lesinski GB, El-Rayes B, Akce M. “Correlative analysis of metformin and nivolumab combination in treatment-refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC),” American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022, New Orleans, LA.
16. Nash R, Collin LJ, Switchenko JM, McCullough LE. “Assessing the contribution of area-level factors to the race disparity in breast cancer mortality in Georgia,” American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022, New Orleans, LA.
17. Olimpiadi Y, Goldenberg AR, Postlewait L, Gillespie T, Arciero C, Styblo T, Cao Y, Switchenko J, Rizzo M. “Learning from COVID experience: Outpatient mastectomies with and without axillary surgery,” American Society of Breast Surgeons (ASBrS) Annual Meeting, April 6-10, 2022, Las Vegas, NV.
18. Tsagkalidis V, Ajay PS, Casabianca AS, Burchard PR, Melucci AD, Chacon A, Switchenko JM, Goyal S, Kooby DA, Carpizo DR, Shah MM. “Exploring the paucity of the diagnosis: Epithelioid hemangioendothelioma of the liver,” 15th World Congress of the International Hepato-Pancreato-Biliary Association, March 30-April 2, 2022, New York, NY.
19. Goldenberg AR, Olimpiadi Y, Postlewait L, Gillespie T, Arciero C, Styblo T, Cao Y, Switchenko J, Rizzo M. “Outcomes of the same-day discharge following breast and axillary surgery requiring drains in the COVID-19 era,” Society of Surgical Oncology (SSO) Annual Meeting, March 9-12, 2022, Dallas, TX.
20. Melucci AD, Chacon AC, Burchard PR, Ullman NA, Tsagkalidis V, Casabianca AS, Reitz A, Swift DA, Goyal S, Switchenko JM, Carpizo DR, Shah MM. “The impact of CA 19-9 on survival in patients with clinical stage I and II pancreatic cancer,” Society of Surgical Oncology (SSO) Annual Meeting, March 9-12, 2022, Dallas, TX.
21. Diab M, Goyal S, Switchenko JM, Alese OB, Shaib WL, Akce M, Wu C, El-Rayes BF. “Characteristics and outcomes of patients with multiple synchronous colonic primaries,” Gastrointestinal Cancers Symposium (GI ASCO), January 20-22, 2022, San Francisco, CA.
22. Draper A, Jung E, Cao Y, Atallah RP, Switchenko JM, Alese OB. “Poorly differentiated histology as a predictive biomarker in patients with advanced gastrointestinal (GI) cancers treated with immunotherapy,” Gastrointestinal Cancers Symposium (GI ASCO), January 20-22, 2022, San Francisco, CA.



23. Melucci AD, Chacon AC, Burchard PR, Ullman NA, Tsakalidis V, Casabianca AS, Reitz AC, Swift DA, Goyal S, Switchenko JM, Carpizo DR, Shah MM. "The impact of CA 19-9 on survival in patients with clinical stage I pancreatic cancer," Gastrointestinal Cancers Symposium (GI ASCO), January 20-22, 2022, San Francisco, CA.
24. Allen PB, Goyal S, Greenwell B, Scribner J, Huen A, Ayers A, Iyer S, Metha A, Goyal G, Krishnasamy S, Porcu P, Sethi T, Switchenko JM, Tarabadkar E, Lechowicz MJ. "No difference in survival among Black patients with Mycosis Fungoides and Sézary Syndrome: A multicenter retrospective analysis," American Society of Hematology (ASH) Annual Meeting, December 11-14, 2021, Atlanta, GA.
25. Allen PB, McCook AA, Switchenko JM, Varma S, Lechowicz MJ, Tarabadkar E. "Risk factors for progression to advanced stage cutaneous T-cell lymphoma: A single center retrospective analysis at the Winship Cancer Institute of Emory University," American Society of Hematology (ASH) Annual Meeting, December 11-14, 2021, Atlanta, GA.
26. Syed Y, Rupji M, Switchenko JM, Eaton B, Olson J, Hoang K, Shu HK, Zhong J. "Treatment trends and survival outcomes in atypical meningioma," Society for Neuro-Oncology (SNO) Annual Conference, November 17-21, 2021, Boston, MA.
27. Taverna LS, Hess CB, Eng TY, Nasti TH, Dhere VR, Kleber TJ, Switchenko JM, Weinberg BD, Rouphael N, Rudra S, Daissou AP, Ahmed R, Khan MK. "Effect of whole-lung low-dose radiation therapy on immunological markers on patients with COVID-19," Annual Biomedical Research Conference for Minority Students (ABRCMS), November 10-13, 2021, Virtual Meeting.
28. Kleber TJ, Switchenko JM, Khan MK. "Real world survival of melanoma with brain metastases treated with immunotherapy with or without intracranial radiotherapy," UGA/Winship Virtual Summit: Advancing Cancer Research in Georgia, October 29<sup>th</sup>, Virtual Meeting.
29. Tian S, Kazzi B, McCook AA, Switchenko JM, Stokes WA, Shelton JW, Kahn SE, Carlisle JW, Steuer CE, Owonikoko TK, Ramalingam SS, Bradley JD, Higgins KA. "Lung stereotactic-body radiation therapy for treatment of oligoprogressive and oligorecurrent metastatic disease: A multi-center analysis," World Conference on Lung Cancer (WCLC) Annual Meeting, September 8-14, 2021, Virtual Meeting.
30. Behera M, Jiang R, Huang Z, Bunn B, Wynes M, Switchenko JM, Scagliotti G, Belani CP, Ramalingam SS. "Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR exon 20 insertion mutation: An IASLC-ASCO CancerLinQ study," World Conference on Lung Cancer (WCLC) Annual Meeting, September 8-14, 2021, Virtual Meeting.
31. Lowe M, Yushak M, Delman K, Rizzo M, Claar C, Schmidt A, Switchenko J, Lawson D, Kudchadkar R. "Winship 4851-19: A pilot study of neoadjuvant and adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma," American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2021, Virtual Meeting.
32. Chacon AC, Melucci AD, Ullman NA, Burchard P, Casabianca AS, Reitz A, Swift DA, Tsagkalidis V, Switchenko JM, Goyal S, Carpizo DR, Shah MM. "Suboptimal lymph node yield is associated with inferior survival in resected stage 1 colon cancer patients," American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2021, Virtual Meeting.
33. Khan MK, Nasti TH, Kleber T, Lawson DH, Yushak M, Switchenko J, Wallington D, Ownikoko T, Ramalingam SS, Kirmani K, Ahmed R, "Phase 1,2 trial of concurrent anti-PD1 and stereotactic radiosurgery (SRS) for brain metastases (NCT02858869)," American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2021, Virtual Meeting.
34. Collin LJ, Ross K, Nash R, Switchenko JM, Jiang RJ, Moubadder L, Miller-Kleinhenz JM, McCullough LE. "New perspectives on racial disparities in breast cancer mortality through the quality of care," American Society of Preventive Oncology Annual Meeting, March 29 – April 1, 2021, Virtual Meeting.

35. Akce M, Rupji M, Switchenko JM, Shaib WL, Wu C, Alese OB, Diab M, Lesinki GB, El-Rayes B. "Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer," Gastrointestinal Cancers Symposium (GI ASCO) Annual Meeting, January 15-17, 2021, Virtual Meeting.
36. Khalil L, Gao X, Switchenko JM, Alese OB, Akce M, Wu C, Diab M, El-Rayes BF Shaib WL. "Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer," Gastrointestinal Cancers Symposium (GI ASCO) Annual Meeting, January 15-17, 2021, Virtual Meeting.
37. Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaas KM, Portell CA, Mejia-Garcia A, Goldsmith S, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar O, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. "Outcomes of patients with relapsed mantle cell lymphoma treated with venetoclax: A Multicenter retrospective analysis," American Society of Hematology (ASH) Annual Meeting, December 5-8, 2020, Virtual Meeting.
38. Greenwell IB, Switchenko JM, Maddocks KJ, Kahl B, Alizadeh AA, Allen PB, Marbury A, Escobar A, Williams M, Valla K, Roberts D, Neely J, Parikh P, Palmer AF, Blum KA, Cohen JB. "Bendamustine, obinutuzumab, and venetoclax as induction in untreated mantle cell lymphoma," American Society of Hematology (ASH) Annual Meeting, December 5-8, 2020, Virtual Meeting.
39. Sadigh G, Switchenko JM, Lava N, Duscak R, Krupinski EA, Meltzer C, Hughes D, Carlos RC. "Longitudinal changes in multiple sclerosis patient-reported financial toxicity and its impact on clinical care and imaging non-adherence," Radiological Society of North America (RSNA) Annual Meeting, November 28 – December 4, 2020, Virtual Meeting.
40. Westergaard S, Switchenko JM, Abugideiri M, Khan MK. "Immunotherapy in combination with surgery and radiation improves local control for primary mucosal melanomas," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 24-28, 2020, Virtual Meeting.
41. Tian S, Switchenko JM, Patel MR, Saba NF, Shin DM, Steuer C, Dhere VR, McDonald MW, Higgins KA, Beitler JJ, Curran WJ, Gillespie TW, Stokes WA, Boyce BJ. "Impact of postoperative radiation therapy timing on survival in HPV-associated oropharyngeal squamous cell carcinoma," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 24-28, 2020, Virtual Meeting.
42. Sudmeier LJ, Morgan T, Mendoza P, Switchenko J, Schreibmann E, Esiashvili N, Eaton B. "Pediatric high-grade glioma patterns of failure by molecular subgroup, American Society for Radiation Oncology (ASTRO) Annual Meeting, October 24-28, 2020, Virtual Meeting.
43. Jiang C, Switchenko J, Lawson D, Yushak M, Khan MK. "Institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 24-28, 2020, Virtual Meeting.
44. Abugideiri M, Janopaul-Naylor J, Switchenko JM, Schreibmann E, Ali AN, McDonald MW, Beitler JJ, Curran WJ, Bruner D, Esiashvili N, Liu T, Patel P. "Reproducibility of an international contouring teaching module for resident education," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 24-28, 2020, Virtual Meeting.
45. Gandrakota N, Lechowicz MJ, Allen PB, Ward K, Switchenko JM. "Incidence of cutaneous T cell lymphoma and air levels of benzene and trichloroethylene," Lymphoma, Leukemia, & Myeloma Congress Annual Meeting, October 21-24, 2020, Virtual Meeting.
46. Bidot S, Monsrud A, Kline M, Speak A, Bilen MA, Switchenko JM, Zhang Y, Gerges AG, Farhat G, Dent EA, Master V, Tinsley M, Harik LR. "Risk stratification of prostatic carcinoma metastatic to the lymph nodes," Prostate Cancer Foundation Scientific Retreat, October 20-23, 2020, Virtual Meeting.

47. Ekpo P, Torres MA, Rupji M, Switchenko JM, Subhedar P, Gogineni K, Bhawe MA. "Outcomes for black versus white women with stage IV breast cancer enrolled on investigator-initiated clinical trials at Emory," American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2020, Chicago, IL.
48. Alese OB, Zhang C, Zakka KM, Kim S, Wu C, Shaib W, Akce M, Chen Z, Switchenko JM, El-Rayes BF. "A cost analysis of managing cancer-related pain among hospitalized U.S. cancer patients," American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2020, Chicago, IL.
49. Abernethy E, Campbell G, Hianik R, Thompson MC, Dixon M, Switchenko JM, Pentz RD. "Videos improve patient understanding of misunderstood chemotherapy terms in a rural population," American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2020, Chicago, IL.
50. Gamboa AC, Meyer BI, Switchenko JM, Rupji M, Lee RM, Turgeon MK, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. "Should adenosquamous esophageal carcinoma be treatment like adenocarcinoma or squamous cell carcinoma," Society of Surgical Oncology Annual Cancer Symposium, March 25-28, 2020, Boston, MA.
51. Royce TJ, Switchenko JM, Zhang C, Spratt DE, Chen RC, Jani AB, Patel SA. "Stereotactic body radiation therapy with androgen deprivation therapy for unfavorable-risk prostate cancer," Genitourinary Cancers Symposium, February 13-15, 2020, San Francisco, CA.
52. Royce TJ, Switchenko JM, Zhang C, Spratt DE, Chen RC, Jani AB, Patel SA. "Utilization of androgen deprivation therapy (ADT) and stereotactic body radiation therapy (SBRT) for localized prostate cancer (PC) in the United States," Genitourinary Cancers Symposium, February 13-15, 2020, San Francisco, CA.
53. Turgeon MK, Gamboa AC, Rupji M, Lee RM, Switchenko JM, Russell MC, Cardona K, Kooby DA, Staley CA, Maithel SK, Shah MM. "Should signet-ring cell histology alter the treatment approach for gastric cancer? A National Cancer Database study," Gastrointestinal Cancers Symposium, January 23-25, 2020, San Francisco, CA.
54. Gamboa AC, Meyer BI, Switchenko JM, Rupji M, Lee RM, Turgeon MK, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. "Should adenosquamous esophageal carcinoma be treatment like adenocarcinoma or squamous cell carcinoma," Gastrointestinal Cancers Symposium, January 23-25, 2020, San Francisco, CA.
55. Shaib WL, Zakka K, Shahin AA, Yared F, Switchenko JM, Wu C, Akce M, Alese OB, Patel PR, McDonald M, El-Rayes BF. "Radiation as a single modality for treatment of localized pancreatic cancer," Gastrointestinal Cancers Symposium, January 23-25, 2020, San Francisco, CA.
56. Allen PB, Switchenko JM, Kim E, Lechowicz MJ. "Mortality and risk factors for bacteremia in patients with cutaneous T-cell lymphoma (CTCL) at Emory University," American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL.
57. Harkins RA, Patel SP, Lee MJ, Switchenko J, Flowers CR. "A data-driven approach to define parsimonious eligibility criteria in first-line clinical trials for diffuse large B-cell lymphoma," American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL.
58. Epperla N, Switchenko JM, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta S, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Martin P, Guo J, Kahl BS, Flowers CR, Cohen JB. "Impact of time to treatment in newly diagnosed patients with mantle cell lymphoma," American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL.
59. Cohen JB, Switchenko JM, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta S, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Martin P, Guo J, Flowers CR, Kahl BS. "Clinical Trial Participation is Associated with Improved Overall Survival in Newly

Diagnosed Patients with Mantle Cell Lymphoma,” American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL.

60. Hill BT, Switchenko JM, Martin P, Churnetski M, Sawalha Y, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Bond D, Badar T, Blum KA, Guo J, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Cohen JB. “Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab (BR),” American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL.
61. Escott C, Madden NA, Schreiber E, Tian S, Cassidy RJ, Sutter AI, Whitaker D, Switchenko JM, Pfister NT, Xu KM, Force S, Ramalingam S, Curran WJ, Higgins KA, Patel PR. “Radiomic analysis of radiation induced fibrosis following stereotactic body radiation therapy,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 15-18, 2019, Chicago, IL.
62. Tian S, Sethi I, Da Silva AJ, Switchenko JM, Owonikoko TK, Schuster DM, Curran WJ, Higgins KA. “Characterization of inter-fraction 18-FDG PET variability during lung SBRT: Results of a prospective pilot study,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 15-18, 2019, Chicago, IL.
63. Allen PB, Clough L, Bayakly AR, Ward K, Khan MK, Chen S, Lechowicz MJ, Flowers CR, Switchenko JM. “An assessment of geographic clustering of cutaneous T-cell lymphoma in the state of Georgia and its association with environmental exposure to benzene and trichloroethylene,” American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4, 2019, Chicago, IL.
64. Marks JA, Switchenko JM, Steuer C, Herrin S, Ryan M, Patel M, El-Deiry M, Shin DM, Beitler JJ, Gillespie T, Saba NF. “Socioeconomic contributions to clinical outcome by HPV status in squamous cell carcinomas of the head and neck (SCCHN): An analysis of NCDB,” American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4, 2019, Chicago, IL.
65. Bean MB, Switchenko JM, Steuer C, McDonald M, Higgins K, Patel M, El-Deiry M, Beitler JJ, Shin DM, Gillespie TW, Saba NF. “Factors associated with metastatic presentation in HPV-related squamous cell carcinoma of the head and neck (SCCHN); a National Cancer Database (NCDB) analysis,” American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4, 2019, Chicago, IL.
66. Allen PB, Kudelka M, Switchenko JM, Esiashvili N, Flowers CR, Khan M, Lechowicz MJ. “Maintenance therapy following total skin electron beam therapy in patients with cutaneous T-cell lymphoma,” American Society of Hematology (ASH) Annual Meeting, December 1-4, 2018, San Diego, CA.
67. Calzada O, Bradley K, Switchenko J, Flowers C, Lechowicz M, Koff J, Gianani R, Chandler C, Mason E, Cohen J. “Utilization of a novel method of detection of CD30 expression in Diffuse Large B-cell Lymphoma,” American Society of Hematology (ASH) Annual Meeting, December 1-4, 2018, San Diego, CA.
68. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski M, Kolla B, Bachanova V, Gerson J, Barta S, Maldonado E, Gordon M, Danilov A, Grover N, Burkhardt M, Karmali R, Sawalha Y, Hill B, Ghosh N, Park S, Epperla N, Bond D, Badar T, Blum K, Hamadani M, Fenske T, Malecek M, Kahl B, Flowers C, Cohen J. “Intensive induction regimens in Mantle Cell Lymphoma patients who defer therapy is not associated with improved progression-free or overall survival,” American Society of Hematology (ASH) Annual Meeting, December 1-4, 2018, San Diego, CA.
69. Ferris MJ, Switchenko JM, Xiao C, Higgins KA, McDonald MW, Eaton BR, Press RH, Tian S, Steuer CE, Baddour HM, Miller AH, Bruner DW, Beitler JJ. “Medulla Dose is Positively Associated with Sensation of Thirst & Midbrain Dose is Inversely Associated with Pain: Prospectively-Collected Patient-Reported Toxicities and Brainstem Dose in Head and Neck Cancer Radiation Therapy,” American Society for Radiation Oncology (ASTRO) Annual Meeting, October 21-24, 2018, San Antonio, TX.

70. Escott CE, Cassidy RJ, Tian S, Switchenko JM, Pfister NT, Xu KM, Eaton BR, Force SD, Ramalingam SS, Curran WJ, Higgins KA. "Angiotensin-converting enzyme inhibitors and /or angiotensin receptor blocker use during stereotactic body radiation therapy: A multi-center analysis," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 21-24, 2018, San Antonio, TX.
71. Subramanian K, Switchenko J, Flowers CR, Esiashvili N, Khan MK. "Consolidative radiation therapy (RT) for advanced stage Hodgkin's lymphoma (HL) may improve progression free survival than ABVD alone for adult patients," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 21-24, 2018, San Antonio, TX.
72. Narayan AS, Switchenko JM, Kane S, Wu C, Alese OB, El-Rayes BF, Shaib WL. "Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer," American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018, Chicago, IL.
73. McDaniels B, Bellcross C, Shaib W, Switchenko J, Dixon M, Pentz RD. "The impact of genetic counseling on patient's knowledge about tumor genomic profiling," American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018, Chicago, IL.
74. Subramanian K, Switchenko J, Flowers CR, Khan MK. "A meta-analysis on ABVD administration in HIV+ patients with advanced stage Hodgkin's lymphoma (HL)," American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018, Chicago, IL.
75. Xu KM, Switchenko JM, Tian S, Escott C, Pfister NT, Gillespie TW, Curran WJ, Khan MK. "More effective systemic therapies are needed for chondrosarcoma: A National Cancer Database (NCDB) analysis," American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018, Chicago, IL.
76. Ip A, Switchenko J, Graiser M, Koff JL, Gupta VA, Lechowicz MJ, Nooka AK, Kaufman JL, Lonial S, Waller EK, Langston A, Flowers CR, Cohen JB. "Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL)," American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018, Chicago, IL.
77. Buchwald ZS, Rossi M, Smith G, Switchenko J, Hauenstein JE, Zhong J, Press RH, Tian S, Saxe DF, Neill SG, Olson JJ, Crocker IR, Curran WJ, Shu HG. "Genomic copy number variation correlates with survival outcomes in high-grade glioma patients," American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018, Chicago, IL.
78. Trivedi S, Switchenko JM, Patel M, Steuer C, El-Deiry M, Higgins K, Solares A, McDonald M, Shin DM, Gillespie T, Beitler JJ, Saba NF. "The effect of hospital volume and insurance status on overall survival in sinonasal carcinomas: A National Cancer Data Base (NCDB) analysis," 2018 Multidisciplinary Head & Neck Cancers Symposium, February 15-17, 2018, Scottsdale, AZ.
79. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Matthew S, Park SI, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB. "Complex karyotype predicts the prognostic impact of WBC count in untreated mantle cell lymphoma and is associated with shortened survival independent of specific cytogenetic abnormalities," American Society of Hematology (ASH) Annual Meeting, December 9-12, 2017, Atlanta, GA.
80. Caulfield S, Switchenko JM, Valla K, Schlafer D, Greenwell IB, Staton AD, Blum KA, Grover NS, Matthew S, Park SI, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB. "Initial salvage approaches for relapse/refractory mantle cell lymphoma have comparable response rates, progression-free and overall survival," American Society of Hematology (ASH) Annual Meeting, December 9-12, 2017, Atlanta, GA.
81. Koff JL, Li J, Zhang XA, Switchenko JM, Flowers CR, Waller EK. "Impact of post-transplant lymphoproliferative disorder subtype on survival," American Society of Hematology (ASH) Annual Meeting, December 9-12, 2017, Atlanta, GA.

82. Cassidy RJ, Switchenko JM, Yushak ML, Madden N, Zaenger D, Monson DK, Beitler JJ, Landry JC, Godette KD, Gillespie TW, Patel KR. "Postoperative Therapy for Scalp Angiosarcomas," Connective Tissue Oncology (CTOS) Annual Meeting, November 8 – 11, 2017, Maui, Hawaii.
83. Abugideiri M, Ferris MJ, Switchenko J, Madden NA, Butket C, Butker EK, Tanenbaum D, Cassidy RJ, Eaton BR, Esiashvili N. "Acute kidney injury after total body irradiation: Associated factors and natural history," International Society of Paediatric Oncology (SIOP) Annual Meeting, October 12-15, 2017, Washington, DC.
84. Tian S, Ferris MJ, Switchenko JM, Magliocca KR, Cassidy RJ, Kendi AT, Tanenbaum DG, Aiken AH, Baugnon KL, Hudgins PA, Patel MR, Saba NF, Curran WJ, Beitler JJ. "Prognostic value of radiographically-defined extracapsular extension is modulated by human papillomavirus status in locally advanced oropharyngeal carcinoma," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 24-27, 2017, San Diego, CA.
85. Abugideiri M, Madden NA, Switchenko J, Butker C, Butker EK, Tanenbaum D, Ferris MJ, Cassidy RJ, Eaton BR, Esiashvili N. "Dose total body irradiation (TBI) influence acute kidney injury in the setting of TBI-based myeloablative conditioning in children undergoing allogeneic hematopoietic stem cell transplantation?," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 24-27, 2017, San Diego, CA.
86. Buchwald Z, Switchenko J, Jhaveri J, Eaton B, Olson JJ, Shu HG, Crocker IR, Curran WJ, Patel KR. "Clinical and dosimetric factors related to radiation necrosis after five fraction radiosurgery for resected brain metastases," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 24-27, 2017, San Diego, CA.
87. Ferris MJ, Liu T, Switchenko JM, Roper J, Ghavidel J, Abugideiri M, Kahn S, Godette KD. "No association between radiation skin dose and acute wound healing complications for TARGIT-IORT," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 24-27, 2017, San Diego, CA.
88. Chowdhary M, Switchenko JM, Marwaha G, Abrams RA, Jhaveri J, Olson J, Shu H, Curran WJ, Khan MK, Patel KR. "Post-treatment neutrophil-to-lymphocyte ratio as a predictor of overall survival in melanoma brain metastases treated with stereotactic radiosurgery," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 24-27, 2017, San Diego, CA.
89. Chowdhary M, Chhabra AM, Switchenko JM, Jhaveri J, Sen N, Abrams RA, Patel KR, Marwaha G. "A quantitative analysis of the current radiation oncologist job market," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 24-27, 2017, San Diego, CA.
90. Ferris MJ, Tian S, Switchenko JM, Eaton BR, Esiashvili N. "Musculoskeletal outcomes and the effect of radiation dose to the vertebral bodies on growth trajectories for long-term survivors of high-risk neuroblastoma," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 24-27, 2017, San Diego, CA.
91. Zeanger D, Lin J, Switchenko J, Meisel J, Subhedar P, Arciero C, Torres M, Patel P. "The influence of histologic grade on outcomes of elderly women with early stage breast cancer treated with breast conserving surgery with or without radiotherapy," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 24-27, 2017, San Diego, CA.
92. Koff JL, Li J, Zhang XA, Switchenko JM, Flowers CR, Waller EK. "Impact of post-transplant lymphoproliferative disorder subtype of survival," International Conference on Malignant Lymphoma, June 14-17, 2017, Lugano, Switzerland.
93. Pentz RD, Pocock H, Pinheiro AM, Switchenko JM, Dixon MD. "Physician communication and patient understanding of molecular testing of tumors," American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2017, Chicago, IL.
94. Steuer CE, Switchenko JM, Griffith C, Patel M, Cassidy RJ, Gillespie TW, Beitler JJ, Owonikoko TK, Chen G, Shin DM, Saba NF. "Institutional treatment volume and outcomes in salivary gland cancer," American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2017, Chicago, IL.

95. Sadigh G, Carlos R, Jiang R, Switchenko JM, Ward K, Applegate K, Duszak R. "Predictors of screening mammography in patients with early vs. advanced stage colorectal and lung cancer: A population-based study," American College of Radiology (ACR) Annual Meeting, May 21-25, 2017, Washington, DC.
96. Russell MC, Switchenko JM, Hawk NN, Gillespie TW, Chawla S. "Presentation, treatment, and survival of younger patients with gastric adenocarcinoma: A National Cancer Data Base (NCDB) study," Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2017, Chicago, Illinois.
97. Cassidy RJ, Patel PR, Zhang X, Press RH, Switchenko JM, Pillai RN, Owonikoko TK, Ramalingam SS, Fernandez FG, Force SD, Curran WJ, Higgins KA. "Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis," Multidisciplinary Thoracic Cancers Symposium Annual Meeting, March 16-18, 2017, San Francisco, CA.
98. Greenwell IB, Valla K, Caufield S, Staton AD, Switchenko JM, Maly J, Blum KA, Grover NS, Mathews S, Park S, Gordon MJ, Danilov A, Epperla N, Fenske T, Hamadani M, Flowers CR, Cohen JB. "Outcomes in mantle cell lymphoma for elderly patients undergoing autologous stem cell transplant in 1<sup>st</sup> complete remission," BMT Tandem Meetings, February 22-26, 2017, Orlando, FL.
99. Cassidy RJ, Cheng E, Switchenko JM, Jiang R, Jhaveri J, Tanenbaum DG, Gillespie TW, McDonald MW, Landry JC. "Nationwide incidence, treatment, and outcomes of patients 80 years and older with rectal adenocarcinomas: Analysis of 5,057 patients," Gastrointestinal Cancers Symposium Annual Meeting, January 19-21, 2017, San Francisco, CA.
100. Zhong J, Patel KR, Switchenko JM, Gillespie TW, Cassidy RJ, Kooby DA, Landry JC. "Comparison of outcomes in patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy (SBRT) versus conventionally fractionated radiation: an analysis of the National Cancer Database," Gastrointestinal Cancers Symposium Annual Meeting, January 19-21, 2017, San Francisco, CA.
101. Staton AD, Greenwell IB, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske T, Hamadan M, Flowers CR, Cohen JB. "Risk stratification of mantle cell lymphoma patients using MIPI, Ki67 percentage and complex cytogenetics," American Society of Hematology (ASH) Annual Meeting, December 3-6, 2016, San Diego, CA.
102. Guidot D, Switchenko JM, Nastoupil L, Koff JL, Blum KA, Maly J, Flowers CR, Cohen JB. "A retrospective evaluation of surveillance imaging in mantle cell lymphoma in the first remission," American Society of Hematology (ASH) Annual Meeting, December 3-6, 2016, San Diego, CA.
103. Calzada O, Bradley K, Switchenko JM, Staton AD, Koff JL, Flowers CR, Cohen JB. "CD30 expression is not acquired at the time of relapse in diffuse large B-cell lymphoma," American Society of Hematology (ASH) Annual Meeting, December 3-6, 2016, San Diego, CA.
104. Terawaki H, Caglar C, Rai A, Switchenko JM, Ayer T, Qiushi C, Flowers CR. "Multi-state mathematical modeling to predict outcomes for follicular lymphoma (FL) patients receiving early first line therapy," American Society of Hematology (ASH) Annual Meeting, December 3-6, 2016, San Diego, CA.
105. Kettle AG, Switchenko JM, Calzada O, Phan A, Farone M, Graiser M, Flowers CR, Cohen JB. "Prolonged progression-free survival is possible in patients with diffuse large B-cell lymphoma receiving >1 salvage therapy before autologous stem cell transplant," American Society of Hematology (ASH) Annual Meeting, December 3-6, 2016, San Diego, CA.
106. Sadigh G, Carlos R, Switchenko J, Ward K, Applegate K, Duszak R. "Breast Cancer Screening in Patients with Newly Diagnosed Lung and Colorectal Cancer: A Population-Based Study of Utilization," Radiological Society of North America (RSNA) Annual Meeting, November 27 – December 2, 2016, Chicago, IL.

107. Sadigh G, Carlos R, Switchenko J, Ward K, Applegate K, Duszak R. “Sociodemographic Predictors of Breast Cancer Screening in Patients with Newly Diagnosed Lung and Colorectal Cancer: A National Population-Based Study,” Radiological Society of North America (RSNA) Annual Meeting, November 27 – December 2, 2016, Chicago, IL.
108. Kendi A, Brandon D, Switchenko J, Wadsworth J, El-Deiry M, Saba N, Schuster D, Subramaniam R. “External validation of therapy response interpretation criteria (Hopkins criteria) with inter-reader reliability, accuracy and progression-free survival outcomes,” Radiological Society of North America (RSNA) Annual Meeting, November 27 – December 2, 2016, Chicago, IL.
109. Ethun C, Lopez-Aguilar A, Switchenko JM, Gillespie T, Delman K, Staley C, Weiss S, Maithel S, Cardona K. “The prognostic value of lymphovascular invasion in soft tissue sarcomas: a U.S. analysis from the National Cancer Data Base (NCDB),” Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting, November 9-12, 2016, Lisbon, Portugal.
110. Danish H, Craven C, Mendoza P, Berstrom C, Aaberg T, Switchenko J, Patel K, Ferris M, Crocker I, Khan M. “Comparative outcomes and toxicity of ruthenium-106 and palladium-103 in the definitive treatment of choroidal melanoma,” American Academy of Ophthalmology (AAO) Annual Meeting, October 15-18, 2016, Chicago, IL.
111. Colbert L, Dharmarajan K, Switchenko J, Taniguchi C, Hall W, Gillespie T, Kooby D, Lipscomb J, Landry J. “Radiation for Pancreatic Adenocarcinoma: an End of Life Treatment? A National Cancer Data Base Analysis,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
112. Danish H, Cassidy R, Switchenko J, Flowers C, Esiashvili N, Jegadeesh N, Khan M. “Consolidative Radiation for Early Stage Diffuse Large B Cell Lymphoma After CHOP or RCHOP: A Surveillance, Epidemiology, And End Results (SEER) Database Analysis,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
113. Edelman S, Waller E, Graiser M, Langston A, Dhere V, Mikell J, Switchenko J, Khan M. “Total Body Irradiation-based Conditioning vs. Chemotherapy-based Conditioning for Allogeneic Hematopoietic Stem Cell Transplant for Acute Leukemia,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
114. Patel P, Schreibmann E, Sutter A, Whitaker D, Switchenko J, Higgins K. “CT Texture Associations with Histology and Outcomes Following Lung SBRT,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
115. Abugideiri M, Patel K, Switchenko J, Magliocca K, Buchwald Z, Delaudio J, Lawson D, Danish H, Beitler J, Khan M. “Adjuvant Radiation Therapy Improved Local Control for Primary Mucosal Melanoma of the Head and Neck,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
116. Ferris M, Zhong J, Switchenko J, Higgins K, McDonald M, Eaton B, Miller A, Bruner D, Xiao C, Beitler J, “CNS Dose is Not Associated with Treatment-Related Fatigue in Patients Undergoing Radiation Therapy for Head and Neck Cancer,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
117. Ferris M, Danish H, Switchenko J, Deng C, Esiashvili N. “Excellent Local Control for Consolidative Radiotherapy without Dose Escalation in High-Risk Neuroblastoma,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.
118. Cassidy R, Switchenko J, Jegadeesh N, Ferris M, Eaton B, Higgins K, Wadsworth J, Saba N, Beitler J. “Lymphovascular Space Invasion is Associated with Local and Regional Failure and Reduced Survival in Node Negative Oral Tongue Cancers,” American Society for Radiation Oncology (ASTRO) Annual Meeting, September 25-28, 2016, Boston, MA.



119. Kendi A, Mudalegundi S, Switchenko J, Lee D, Halkar R, Chen A. "Does FDG PET/ CT alter management of well differentiated thyroid cancer (WDTC) in the follow up period?," American Head & Neck Society (AHNS) 9<sup>th</sup> International Conference on Head and Neck Cancer, July 16-20, 2016, Seattle WA.
120. Calzada O, Switchenko J, Maly J, Blum K, Grover N, Mathews S, Park S, Gordon M, Danilov A, Flowers C, Cohen J. "Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma," American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016, Chicago, IL.
121. Greenwell I, Staton A, Lee M, Switchenko J, Maly J, Blum K, Grover N, Mathews S, Park S, Gordon M, Danilov A, Flowers C, Cohen J. "Complex karyotype is associated with inferior progression-free and overall survival in Mantle Cell Lymphoma," American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016, Chicago, IL.
122. Lee M, Switchenko J, Thomas J, Koff J, Nastoupil L, Lechowicz M, Langston A, Flowers C, Cohen J. "Complex karyotype in mantle cell lymphoma (MCL) is associated with inferior progressive-free survival in patients (pts) receiving R-HyperCVAD followed by autologous stem cell transplant," American Hematology Society Annual Meeting, December 5-8, 2015, Orlando, FL.
123. Chowdhary M, Patel K, Lawson D, Switchenko J, Kudchadkar R, Khan M. "Potential for increased risk of radiation necrosis with BRAF inhibitor and stereotactic radiosurgery," Society for Melanoma Research 2015 Congress, November 18-21, 2015, San Francisco, CA.
124. Morgan T, Crocker I, Switchenko J, Ali A, Shu H. "Radiation therapy for MRI-defined meningiomas: Long-term outcomes from a single institution," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 18-21, 2015, San Antonio, TX.
125. Heumann T, Danish H, Switchenko J, Esiashvili N, Lechowicz M, Flowers C, Khan M. "Cutaneous CD30+ Mycosis Fungoides: Response to Rotational Total Skin Electron Irradiation," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 18-21, 2015, San Antonio, TX.
126. Cassidy R, Switchenko J, Jegadeesh N, Rajpara R, Esiashvili N, Flowers C, Khan M. "The Role of Consolidative Radiotherapy in Elderly Patients with Diffuse Large B-cell Lymphoma (DLBCL)," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 18-21, 2015, San Antonio, TX.
127. Oliver D, Patel K, Switchenko J, Parker D, Lawson D, Delman K, Kudchadkar R, Khan M. "Roles of Adjuvant and Salvage Radiation Therapy for Desmoplastic Melanoma," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 18-21, 2015, San Antonio, TX.
128. Kendi A, Magliocca K, Corey A, Galt J, Switchenko J, Wadsworth J, El-Deiry M, Hudgins P, Schuster D, Saba N. "Is there any role of PET/CT parameters to assess primary and metastatic parotid tumors?," 2015 Annual Meeting of the American Society of Head and Neck Radiology, September 9-13, 2015, Naples, FL.
129. Hannan L, Switchenko J, Behera M, Pillai R, Khuri F, Ramalingham S, Gillespie T, Owonikoko T. "Survival impact of adjuvant radiation and chemotherapy in patients with typical and atypical pulmonary carcinoids," International Association for the Study of Lung Cancer (IASLC) 16<sup>th</sup> World Conference on Lung Cancer, September 6-9, 2015, Denver, CO.
130. Switchenko J, Waller L, Ryan P. "Dimension Reduction for Chemical Exposure Risk Assessment," Statistical Approaches for Assessing Health Effects of Environmental Chemical Mixtures in Epidemiology Studies Workshop, July 13-14, 2015, Research Triangle Park, NC.
131. Heumann T, Esiashvili N, Parker S, Switchenko J, Lechowicz M, Flowers C, Khan M. "Total Skin Electron Irradiation (TSEI) Using Rotational Technique For Cutaneous T- Cell Lymphoma," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 14-16, 2014, San Francisco, CA.

132. Lim T, Prabhu R, Switchenko J, Mister D, Torres M. "Skin Sparing Mastectomy and Immediate Reconstruction in Locally Advanced Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Post-Mastectomy Radiotherapy: Long-term Oncologic and Patient Reported Quality of Life Outcomes," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 14-16, 2014, San Francisco, CA.
133. Colbert L, Hall W, Mosley C, Seldon C, Mittal P, Switchenko J, Mikell J, Mavraj G, Yu D, Landry J, Curran W. "The Use of MRI For GTV Delineation In Borderline and Locally Advanced Pancreatic Cancer Increases Local Control In Patients Treated With Intensity Modulated Radiation Therapy," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 14-16, 2014, San Francisco, CA.
134. Kandula S, Switchenko J, Fasola C, Mister D, Torres M. "The Influence of Receptor Status on Locoregional Recurrence Risk among Breast Cancer Patients with Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Mastectomy," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 14-16, 2014, San Francisco, CA.
135. Huff B, Switchenko J, Dwivedi B, Curran W, Crocker I, Shu H. "Identification of a 12-gene Expression Signature from the Cancer Genome Atlas Prognostic for Survival in Glioblastoma," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 14-16, 2014, San Francisco, CA.
136. Cassidy R, Switchenko J, Wadsworth J, El-Deiry M, Saba N, Higgins K, Beitler J. "Squamous Cell Carcinoma of the Oral Tongue: Exploring New Trends," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 14-16, 2014, San Francisco, CA.
137. Saba N, Rossi M, Dwivedi B, Switchenko J, Magliocca K, Ramalingam S, Owonikoko T, Khuri F, Chen Z, Kowalski J, Shin D. "Predictive value of gene expression signatures in pre-malignant lesions of the head and neck for response to chemoprevention with EGFR and COX-2 inhibitors," American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3, 2014, Chicago, IL.
138. Pentz R, White T, Dossul T, Hendershot K, Dixon M, Salvador C, Switchenko J, Harvey D. "Development of a patient preference assessment tool for cancer patients considering phase I research," American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3, 2014, Chicago, IL.
139. Lutterman A, Switchenko J, Pan T, Read W. "Utilizing nomogram-predicted outcomes as the control group in randomized clinical trials," American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3, 2014, Chicago, IL.
140. Hall W, Nickleach D, Switchenko J, Lipscomb J, Goodman M, Ward K, Gillespie T. "The Management of Adenocarcinoma of the Prostate in Rural Georgia: A Population Based Analysis," 2014 Genitourinary Cancers Symposium, January 30-February 1, 2014, San Francisco, CA.
141. Bulka C, Nastoupil L, Koff J, Bernal L, Ward K, Bayakly R, Switchenko J, Waller L, Flowers C. "Relationship Between Residential Proximity to Environmental Protection Agency (EPA) Designated Toxic Release Sites and the Risk of Diffuse Large B-Cell Lymphoma (DLBCL)," American Society of Hematology (ASH) Annual Meeting, December 7-10, 2013, New Orleans, LA.
142. Bulka C, Nastoupil L, Switchenko J, Ward K, Bayakly R, Waller L, Flowers C. "Spatial Epidemiology of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the State of Georgia," American Society of Hematology (ASH) Annual Meeting, December 7-10, 2013, New Orleans, LA.
143. Hall W, Colbert L, Nickleach D, Switchenko J, Gillespie T, Lipscomb J, Hardy C, Kooby D, Prabhu R, Landry J. "The Influence of Radiation Therapy Dose Escalation on Overall Survival in Unresectable Pancreatic Adenocarcinoma," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 22-25, 2013, Atlanta, GA.

144. Eaton B, Losken A, Okwan-Duodu D, Schuster D, Switchenko J, Mister D, Godette K, Torres M. "Oncoplastic Reduction Mammoplasty in Patients with Breast Cancer: Implications for Radiotherapy," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 22-25, 2013, Atlanta, GA.
145. Mikell J, Waller E, Rangaraju S, Switchenko J, Ali Z, Graiser M, Hall W, Langston A, Esiashvili N, Khan M. "Similar Survival for Patients Undergoing Single Fraction TBI versus Myeloablative TBI as Conditioning for Allogeneic Transplant in Acute Leukemia," American Society for Radiation Oncology (ASTRO) Annual Meeting, September 22-25, 2013, Atlanta, GA.
146. Ali A, Switchenko J, Perino L, Flood A, Swartz H. "A Clinical Analysis of Emesis as a Medical Screening Diagnostic for Radiation Dose," Radiation Research Society Annual Meeting, September 14-18, 2013, New Orleans, LA.
147. Kowalski J, Switchenko J, Dwivedi B, Nickleach D, Moreno C. "Methylation Signatures Specific to Triple Negative Breast Cancer Subtypes," American Association for Cancer Research: Chromatin and Epigenetics in Cancer, June 19-22, 2013, Atlanta, GA.
148. Kowalski J, Gandhi K, Switchenko J, Liu Y, Kim S, Doho G, Kim SJ, Yang R, Chen L, Qin Z, Newman S, Moreno C, Vertino P, Bernal-Mizrachi L, Rossi M, Lonial S, Boise L. "Integrative, Multi-Platform, Whole-Genome Analyses Identify Clinically Relevant Common- and Cell-Specific Signatures in Multiple Myeloma," American Society of Hematology (ASH) Annual Meeting and Exposition, December 8-11, 2012, Atlanta, GA.
149. Echt V, Gillespie T, Petros J, Lipscomb J, Switchenko J, Nickleach D, Gao J, Herell L, Britan L, Rowell J, Goodman M. "Perceived Influences on Early Stage Prostate Cancer Treatment Decision Making in At-Risk Men: The Role of Age, Numeracy, and Health Literacy," Gerontological Society of America (GSA) Annual Scientific Meeting, November 14-18, 2012, San Diego, CA.
150. Ali A, Switchenko J, Kim S, Kowalski J, Higgins K, Beitler J. "A SEER-based Probability Model using HPV Status and Lymph Node Levels to Predict Primary Head & Neck Tumor Site for Squamous Cell Cancer Confined to Cervical Lymph Nodes," American Society for Radiation Oncology (ASTRO) Annual Meeting, October 28-31, 2012, Boston, MA.
151. Ainslie K, Switchenko J, Gandhi K, Newman S, Qin Z, Yang R, Chen L, Pauly R, Doho G, Vertino P, Moreno C, Bernal-Mizrachi L, Rossi M, Lonial S, Boise L, Kowalski J. "Outlier Analysis to Filter Translocations from Next Generation Sequence Data," IEEE International Conference on Bioinformatics and Biomedicine, October 4-7, 2012, Philadelphia, PA.
152. Jacob JT, Chernetsky S, Dent M, Switchenko J, Easley K, Garrett G, Graham K, Holder C, Robichaux C, Steinberg JP. "Comparison of a Novel Silver-Coated Catheter Access Device and a Standard Catheter Access Device: A Dual center Cross-over Study," Annual Meeting of the Infectious Diseases Society of America (IDSA), October 20-23, 2011, Boston, MA.
153. Kilgo P, Switchenko J, Superak H, Weiss P, Elon L, Schmotzer B, Waller L. "Pitch F/X as a Scouting Tool: Using Advanced Graphical Methods to Scout Hitters," Society for American Baseball Research (SABR) Meeting, July 6-10, 2011, Long Beach, CA.

---

## **GRANT SUPPORT:**

### **ACTIVE:**

Title: Winship Cancer Institute Cancer Center Support Grant

PI: Suresh Ramalingam

Dates: 04/01/23-03/31/28

Funding agency: NIH P30 Center Grant, Award Number: 2P30CA138292

Role: Co-investigator (10%)

Title: Mechanisms of SIRT2 Function in the DNA Damage Response  
PI: David Yu  
Dates: 07/01/19-06/30/24  
Funding agency: NIH R01, Award #: CA178999  
Role: Co-investigator (5%)

Title: Circulating Tumor Cell Clusters as a Novel Biomarker for Medulloblastoma Treatment  
PI: Tobey MacDonald  
Dates: 01/01/20-12/31/23  
Funding agency: V Foundation  
Role: Co-investigator (10%)

Title: Lung Cancer SPORE  
PI: Suresh Ramalingam  
Dates: 07/01/20-08/31/23  
Funding agency: NIH, Award Number: 1P50CA217691-01  
Role: Co-investigator (10%)

Title: Targeting immune stroma interactions in pancreatic cancer  
PI: Gregory Lesinski  
Dates: 09/15/17-06/30/24  
Funding agency: NIH, Award Number: R01CA228406-2  
Role: Co-investigator (5%)

Title: Improving our understanding of breast cancer mortality disparities through recurrence  
PI: Lauren McCullough  
Dates: 04/01/21-3/31/26  
Funding agency: NIH R01, Award Number: 1R01CA259192-01  
Role: Co-investigator (10%)

Title: A Multi-institutional Pilot Study to Evaluate Safety and Feasibility of Talazoparib, Radiotherapy and Atezolizumab in gBRCA wild-type Patients with PD-L1+ Metastatic Triple Negative Breast Cancer  
PI: Mylin Torres  
Dates: 07/01/20-6/30/23  
Funding agency: Pfizer  
Role: Co-investigator (8%)

Title: Elucidating SAMHD1 in DNA Double-Strand Break Repair  
PI: David Yu  
Dates: 07/01/20-06/30/25  
Funding agency: NIH R01  
Role: Co-investigator (3%)

Title: Modulation of Mcl-1 for treatment of lung cancer  
PI: Xingming Deng  
Dates: 07/01/21-06/30/26  
Funding agency: NIH R01  
Role: Co-investigator (5%)

Title: Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade  
PI: Gregory Lesinski  
Dates: 07/01/21-06/30/23  
Funding agency: NIH R21  
Role: Co-investigator (2.5%)

Title: Novel Chemical Tools for Discovery of Lung Cancer-Specific Biomarkers

PI: Monika Raj

Dates: 04/01/22-03/31/26

Funding agency: American Cancer Society

Role: Co-investigator (3%)

Title: Genomic and Microenvironmental Determinants, Temporal Dynamics, and Efficacy of Radiation-Based Combination Therapies

PI: David Yu

Dates: 07/01/22-06/30/27

Funding agency: NIH U54

Role: Co-investigator (2%)

Title: Patient Reminders and Self-referrals Via Online Patient Portals and Text Messaging

PI: Patricia Balthazar

Dates: 07/01/22-06/30/24

Funding agency: Association of University Radiologists, GERRAF Award

Role: Co-investigator (2%)

Title: Emory-Georgia TB Research Training Program

PI: Henry Blumberg

Funding agency: NIH D43

Role: Instructor (0%)

\*\*\* Funded\*\*\*

Title: Atorvastatin to Reduce Cisplatin-Induced Hearing Loss in Head and Neck Cancer Patients

PI: Nikki Schmitt

Dates: 04/01/23-03/31/28

Funding agency: NIH U01

Role: Co-investigator (10%)

\*\*\* Funded \*\*\*

Title: Preoperative immunotherapy in Hepatocellular Carcinoma

PI: Gregory Lesinski

Dates: 04/01/22-03/31/24

Funding agency: NIH R21

Role: Co-investigator (5%)

\*\*\*Funded\*\*\*

Title: Elucidating and Exploiting SAMHD1 for Breast Cancer Therapy

PI: David Yu

Dates: 10/01/23-09/30/27

Funding agency: DOD

Role: Co-investigator (5%)

## **PENDING:**

Title: WINSHIP5958: CARE-HPV: ctDNA-Based Personalized Adjuvant Radiotherapy for Early-Stage HPV-Associated Oropharyngeal Cancer

PI: James Bates

Dates: 09/23/23-12/31/30

Funding agency: Sysmex Inostics, Inc.

Role: Co-investigator (2%)

Title: Blueberry Extract as an Immunoprevention Strategy for Oral Carcinogenesis

PI: Nikki Schmitt

Dates: 04/01/24-03/31/26  
Funding agency: NIH R21  
Role: Co-investigator (3%)

Title: Investigating heme-regulated venetoclax resistance in multiple myeloma  
PI: Mala Shanmugam  
Dates: 04/01/24-03/31/29  
Funding agency: NIH R01  
Role: Co-investigator (3%)

Title: Ethiopia-Emory TB Research Training Program (EETB-RTP)  
PI: Henry Blumberg  
Funding agency: NIH D43  
Role: Instructor (0%)

Title: Improving myeloma prevention through immune-modulation  
PI: Madhav Dhodapkar  
Dates: 04/01/24-03/31/29  
Funding agency: NIH R01  
Role: Co-investigator (3%)

Title: Emory University Lung Cancer SPORE  
PI: Suresh Ramalingam  
Dates: 06/01/24-05/31/29  
Funding agency: NIH P50  
Role: Co-investigator – Core co-leader (10%)

Title: Targeting cancer mitochondrial metabolism to improve immunotherapy  
PI: Yong Teng  
Dates: 09/01/23-08/31/28  
Funding agency: NIH R01  
Role: Co-investigator (5%)

Title: Geographic and Myeloid Determinants of Racial Disparities in Cardiovascular Morbidity and Mortality in Patients with Prostate Cancer  
PI: Sagar Patel  
Dates: 07/01/23-06/30/24  
Funding agency: Georgia Center for Oncology Research and Education (Georgia CORE)  
Role: Co-investigator (5%)

Title: Developing a Robotic Bronchoalveolar Lavage to Enhance Microbe Detection and Diminish Morbidity in critically ill children  
PI: Kirsten Williams  
Dates: 12/01/23-11/30/25  
Funding agency: NIH R21  
Role: Co-investigator (1%)

Title: High Fiber Diet to Mitigate Toxicity and Enhance Immunotherapy Response in Melanoma Patients  
PI: Terry Hartman  
Dates: 12/01/23-11/30/26  
Funding agency: NIH R34  
Role: Co-investigator (2.5%)

Title: Investigating the oncogenic role of AMPK in LKB1-mutant lung cancer  
PI: Melissa Gilbert-Ross  
Dates: 09/01/23-08/31/28

Funding agency: NIH R01  
Role: Co-investigator (5%)

Title: Exploiting SAMHD1 in Directing Radiation and Immunologic Dynamics  
PI: David Yu  
Dates: 09/01/23-08/31/28  
Funding agency: NIH R01  
Role: Co-investigator (5%)

Title: Understanding and Exploiting SAMHD1 for Pancreatic Cancer Therapy  
PI: David Yu  
Dates: 10/01/23-09/30/26  
Funding agency: DOD  
Role: Co-investigator (3%)

Title: Investigating dysregulated heme homeostasis in promoting BCL-2 dependence in multiple myeloma  
PI: Mala Shanmugam  
Dates: 07/01/23-06/30/28  
Funding agency: NIH R01  
Role: Co-investigator (5%)

Title: The Phosphodiesterase ROle in Progressive Early and Late Chronic Lung Disease after hematopoietic cell transplantation (PROPEL CLD)  
PI: Kirsten Williams  
Dates: 07/01/23-06/30/26  
Funding agency: NIH R01  
Role: Co-investigator (5%)

Title: Targeting ribonucleotide reductase for lung cancer therapeutics  
PI: Xingming Deng  
Dates: 07/01/23-06/30/28  
Funding agency: R01  
Role: Co-investigator (5%)

Title: Targeting MERTK to improve therapeutic response to ICB in TNBC  
PI: Douglas Graham (GA Tech PI: Susan Thomas)  
Dates: 09/01/23-08/31/26  
Funding agency: DOD (Subcontract: Georgia Tech)  
Role: Co-investigator (5%)

Title: Elucidating and Exploiting CETN1 in Small Cell Lung Cancer  
PI: David Yu  
Dates: 09/01/23-08/31/25  
Funding agency: DOD Lung Cancer Research Program  
Role: Co-investigator (5%)

Title: The Value of Patient Engagement and PROs (REPROSENT) in Pancreatic Cancer  
PI: Maria Diab  
Dates: 07/01/23-06/30/26  
Funding agency: Gateway for Cancer Research  
Role: Co-investigator (1%)

**COMPLETED:**

Title: Emory Winship Cancer Institute Cancer Center Support Grant  
PI: Suresh Ramalingam

Dates: 04/01/17-03/31/23  
Funding agency: NIH, Award Number: 2P30CA138292-09  
Role: Co-investigator (20%)

Title: Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging

PI: David Schuster  
Dates: 12/01/20-11/30/22  
Funding agency: NIH R21  
Role: Co-investigator (2%)

Title: Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients

PI: Mylin Torres  
Dates: 10/01/18-09/30/22  
Funding agency: Pfizer ASPIRE  
Role: Co-investigator (10%)

Title: Drivers of racial disparities in cutaneous T-cell lymphoma in the state of Georgia

PI: Pamela Allen/Lauren McCullough  
Dates: 09/01/21-08/31/22  
Funding agency: Synergy Award  
Role: Co-investigator (2%)

Title: Exploiting SIRT2 for Breast Cancer Therapy

PI: David Yu  
Dates: 08/01/19-07/31/22  
Funding agency: DOD Breast Cancer Research Program (BCRP), Award #: BC180883  
Role: Co-investigator (6%)

Title: Enhancing immune therapy in pancreatic cancer by targeting IL-6

PI: Gregory Lesinski  
Dates: 08/01/20-07/31/22  
Funding agency: NIH, Award Number: R01CA208253-05  
Role: Co-investigator (5%)

Title: Breast cancer disparities in recurrence and mortality

PI: Lauren McCullough  
Dates: 07/01/19-06/30/22  
Funding agency: Susan G. Komen Foundation, Award #: CCR19608510  
Role: Co-investigator (10%)

Title: Pilot Feasibility of Cost Communication and Optimization (CostCOM) in Cancer

PI: Gelareh Sadigh  
Dates: 11/01/20-07/31/21  
Funding agency: ECOG-ACRIN Cancer Control and Outcomes Pilot Project Award  
Role: Co-investigator (5%)

Title: Melanoma immunotherapy targeting sentinel lymph nodes

PI: E. Waller  
Dates: 07/01/16-06/30/21  
Funding agency: NIH R01 (Subcontract: Georgia Tech). Award Number: RG983-G1  
Role: Co-investigator (3.5%)

Title: Effect of GCR exposure on the functional status of the DNA repair Machinery and its contribution to cancer risk

PI: William Dynan



Dates: 07/01/18-06/30/21  
Funding agency: NASA, Award Number: 80NSSC18K1116  
Role: Co-investigator (3%)

Title: Pilot Feasibility Study of Out-of-Pocket Cost Communication and Supportive Financial Services to Reduce Financial Toxicity Among Multiple Sclerosis Patients  
PI: Gelareh Sadigh  
Dates: 01/01/20-12/31/20  
Funding agency: National Multiple Sclerosis (MS) Society  
Role: Co-investigator (5%)

Title: Development of a comprehensive research program in mantle cell lymphoma in the ibrutinib era  
PI: Kristie Blum  
Dates: 8/12/17-8/31/20  
Funding agency: NIH NCI, Award Number: 7K24CA201524-03  
Role: Biostatistician (3%)

Title: Understanding and Exploiting SIRT2/BRCA1 Interplay for Ovarian Cancer Therapy  
PI: David Yu  
Dates: 09/01/17-08/31/20  
Funding agency: Department of Defense (2016 Ovarian Cancer Research Program Pilot Award), Award Number: OC160540  
Role: Co-investigator (2%)

Title: Improving Pancreatic Cancer Therapy by Exploiting SAMHD1 in DNA Repair  
PI: David Yu  
Dates: 08/19/17-08/31/20  
Funding agency: Department of Defense, Award Number: CA160771  
Role: Co-investigator (4%)

Title: Patient-Reported Financial Toxicity in Multiple Sclerosis: Predictors and Association with Neuroimaging and Medication Non-Adherence  
PI: Gelareh Sadigh  
Dates: 07/01/18-06/30/20  
Funding agency: Association of University Radiologists  
Role: Co-investigator (2.5%)

Title: Assessment of bias in LexisNexis residential history with non-Hodgkin lymphoma (NHL) patients in Georgia  
PI: Jeffrey Switchenko  
Dates: 07/01/19-06/30/20  
Funding agency: Biostatistics, Epidemiology and Research Design (BERD) program of the Georgia CTSA  
Role: PI (0%)

Title: Care Pathway Development, Implementation, and Assessment to Improve Outcomes in African American (AA) Breast Cancer Patients  
PI: Mylin Torres  
Dates: 01/01/18-01/01/20  
Funding agency: National Comprehensive Cancer Network (NCCN) and Pfizer Independent Grants for Learning & Change (IGLC) Clinical Pathways in Breast Cancer  
Role: Co-investigator (3%)

Title: Targeted immunotherapy for melanoma  
PI: Jeffrey Switchenko (GA Tech PI: Thomas)  
Dates: 09/01/16-08/31/19  
Funding agency: Department of Defense (Subcontract: Georgia Tech), Award Number: RH269-G1  
Role: Emory PI (3%)

Title: Microsimulation modeling to evaluate the clinical effectiveness of novel cancer therapy  
PI: Christopher Flowers  
Dates: 09/01/16-08/31/19  
Funding agency: Burroughs Wellcome Fund, Award Number: 1016433  
Role: Biostatistician (3%)

Title: Genetic characterization of aggressive lymphoma in African Americans  
PI: Christopher Flowers  
Dates: 10/01/16-08/31/19  
Funding agency: V Foundation for Cancer Research  
Role: Co-investigator (8%)

Title: Mentored patient oriented research in lymphoma  
PI: Christopher Flowers  
Dates: 07/01/16-08/31/19  
Funding agency: NIH, Award Number: 1K24CA208132-01  
Role: Biostatistician (5%)

Title: Patient-Reported Financial Toxicity in Multiple Sclerosis: Predictors and Association with Neuroimaging and Medication Non-Adherence  
PI: Gelareh Sadigh  
Dates: 07/01/18-06/30/19  
Funding agency: RSNA  
Role: Co-investigator (5%)

Title: Informatics tools for quantitative digital pathology profiling and integrated prognostic modeling  
PI: Lee Cooper  
Dates: 04/01/18-05/31/19  
Funding agency: NIH  
Role: Co-investigator (5%)

Title: A phase I/II Study of Ixazomib and Ibrutinib in relapsed/refractory mantle cell lymphoma  
PI: Jonathon Cohen  
Dates: 07/01/16-06/30/19  
Funding agency: American Society of Hematology  
Role: Biostatistician (5%)

Title: Identifying diet patterns linked to environmental exposures with implications for cancer  
PI: Terry Hartman  
Dates: 05/14/18-08/31/18  
Funding agency: Winship pilot grant  
Role: Co-investigator (0%)

Title: Understanding and exploiting EZH2 in small cell lung cancer  
PI: David Yu  
Dates: 11/01/16-10/31/18  
Funding agency: Lung Cancer Research Fund  
Role: Co-investigator (1%)

Title: Breast cancer immunotherapy targeting sentinel lymph nodes  
PI: Jeffrey Switchenko (GA Tech PI: Susan Thomas)  
Dates: 10/2/15-10/1/18  
Funding agency: Susan G. Komen Foundation (Subcontract: Georgia Tech), Award Number: RG320-G1  
Role: Emory PI (3%)

Title: Emory Winship Cancer Institute Cancer Center Support Grant  
PI: Walter Curran  
Dates: 04/07/09-03/31/17  
Funding agency: NIH, Award Number: 4P30CA138292-08  
Role: Co-investigator (20%)

Title: Quantifying BTEX exposure: Improving our Understanding of the Relationship between Proximity to Toxic Release Sites and Risk of Non-Hodgkin Lymphoma  
PI: Christopher Flowers/Jeffrey Switchenko  
Dates: 03/01/15-02/29/16  
Funding agency: Winship Cancer Institute's Cancer Prevention and Control Pilot Project Grant  
Role: Co-principal investigator

Title: Development of statistical models for understanding the relationship between lymphoma risk and toxic release exposures  
PI: Jeffrey Switchenko  
Dates: 04/01/14-03/31/15  
Funding agency: Pam Rollins Research Award  
Role: Principal investigator (5%)

Title: Physically based biodosimetry for triage after a large radiation incident: a clinical analysis of emesis as a medical screening diagnostic for radiation dose  
PI: Arif Ali  
Dates: 08/20/13-08/19/15  
Funding agency: Dartmouth College, Award Number: 1266  
Role: Co-investigator (5%)

Title: Informed decision-making in early stage prostate cancer  
PI: Theresa Gillespie  
Dates: 08/01/12-09/30/12  
Funding agency: CDC SIP  
Role: Biostatistician

---

## AWARDS:

- Award for Outstanding Service to Winship Clinical and Translational Research Committee, 2016
- 2014 Pam Rollins Research Award
- Oak Ridge Institute for Science and Education (ORISE) fellow at Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases (DFWED), 2011-2012.
- Biostatistics in Genetics, Immunology, and Neuroimaging (BGIN) training grant fellow, a pre-doctoral training grant awarded by the National Institutes of Health, 2006-2011. (PI: Lance Waller, Emory University).
- Full-tuition scholarship recipient:
  - 1<sup>st</sup> annual Summer Institute in Statistics and Modeling in Infectious Diseases funded by the University of Washington (2009).
  - Ecology and Evolution of Infectious Disease 7th Annual Workshop and Conference at the University of Georgia funded by Colorado State University (2009).
  - Boston University Summer Institute in Biostatistics (2005) funded by the National Heart, Lung, and Blood Institute.
- 2011 USA Today Sports Weekly Award for Best Poster Presentation - Society for American Baseball Research (SABR) Meeting, July 6-10, 2011, Long Beach, CA.
- 2004 Fall All-Academic New England Small College Athletic Conference (NESCAC) team for cross-country

---

## RESEARCH INTERESTS:

- Cancer prevention and control
  - Spatial analysis of public health data
  - Utilization of cancer registry data and residential history data
- 

**REFEREE:**

- *Ammons Scientific*
  - *Journal of Geographic Systems*
  - *Frontiers in Oncology*
  - *Pakistan Journal of Statistics*
  - *Cancer Management and Research*
  - *Public Health*
  - *Research Methods in Medicine and Health Sciences*
  - *Cancer Causes & Control*
  - *JAMA Oncology*
  - *Environmental Research*
  - *Cancer*
  - *Statistics in Biosciences*
  - *BMJ Open*
  - *Therapeutic Advances in Medical Oncology*
- 

**EDITORIAL BOARD:**

- *Cancer*, 2021-present
- 

**PROFESSIONAL SERVICE:**

- ENAR 2010 Spring Meeting, volunteer, New Orleans, LA.
  - JSM 2015, Session Chair, Seattle, WA.
- 

**PROFESSIONAL/COMMITTEE MEMBERSHIPS:**

- Member of American Statistical Association, 2004-present
  - Member of American Statistical Association, Georgia Chapter, 2019-present
  - Member of the Society for Clinical Trials, 2012-2015
  - Protocol Review and Monitoring Committee (PRMC) at Winship Cancer Institute, 2012-present
  - Oncology Journal Club at Winship Cancer Institute, 2013-present
  - Student Recruitment Committee in Department of Biostatistics and Bioinformatics, 2014-2016
  - Associate member of the Cancer Prevention and Control program at Winship Cancer Institute, 2015-present
  - Winship DATA Shared Resource Committee, 2017-present
  - Radiation Oncology Journal Club, 2017-present
  - Awards Committee (Chair) in Department of Biostatistics and Bioinformatics, 2018-present
  - Website Committee in Department of Biostatistics and Bioinformatics, 2018-2019
  - Ph.D. Admissions Committee in Department of Biostatistics and Bioinformatics, 2019-2022
  - Winship Artificial Intelligence (AI) & Data Science Task Force, 2022-present
-